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Evaluation of the Antagonism of Nicotine by Mecamylamine and Pempidine
in the Brain.
ABSTRACT

A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Thomas Jeffrey Martin

Virginia Commonwealth University

Director: Dr. Billy R. Martin
Antagonists have been crucial in the characterization of nicotine's phannacology. Initial
evidence for the existence of central nicotinic receptors was based on the fact that nicotine
produced a number of behavioral effects that were antagonized by ganglionic blockers that
crossed the blood-brain barrier, such as mecamylamine and pempidine. Although the
mechanism of action of these compounds has been studied extensively in the periphery,
little is known about their mechanisms of action in the brain. These compounds are
thought to

be noncompetitive antagonists due to the fact that they do not compete for

agonist binding to brain homogenate in vitro. However, pharmacological evidence in
support of noncompetitive antagonism is lacking.
Dose-response curves for nicotine were determined in the presence of various doses of
pempidine for depression of spontaneous activity and antinociception in mice. Pempidine
was found to shift the dose-response curves for these effects of nicotine in a manner
consistent with noncompetitive antagonism. A number of mecamylamine analogs were
investigated for antagonism of these central effects of nicotine as well. These studies
revealed that the

N-, 2-, and 3-methyls were crucial for optimal efficacy and potency and

suggests that these compounds possess a specific mechanism of action, possibly involving
a receptor. Furthermore, the structure-activity relationships for the mecamylamine analogs

xiii

were found to be different than that previously reported for the agonists, suggesting that
they do not act at the

same

site.

The binding of [3H]-L-nicotine and [3H]-pempidine was studied in vitro to mouse brain
homogenate and in situ to rat brain slices. The in situ binding of rH]-L-nicotine to rat
brain slices was quantitated autoradiographically to discrete brain
absence of 1, 10 and 100 J.l.M nicotine and pempidine.

areas

in the presence and

Pempidine did not effectively

displace [3H]-L-nicotine binding. The studies with [3H]-pempidine failed to demonstrate
saturable binding.
The evaluation of the antagonism of nicotine by mecamylamine and pempidine
presented in this thesis supports a noncompetitive action of these compounds in the brain.
The shift in the dose-response curves for nicotine, the structure-activity relationship for
mecamylamine analogs and the binding studies

are

consistent with this hypothesis. The

noncompetitive nature of these compounds suggests that they do not compete for the
binding site of the agonist, and that endogenous nicotinic antagonists may exist in the
brain.

I. General Introduction

A. Preface
Interest in the phannacology of nicotine arose due to the prevalence of tobacco use
following the commercialization and production of finished products from tobacco.
Following its isolation from tobacco and subsequent synthesis, nicotine was shown to
produce a myriad of pharmacological effects both centrally and peripherally.
Investigations of nicotine's phannacology resulted in the characterization of a major
neuronal system that came to be known as the nicotinic cholinergic system. Nicotine was
also one of the first compounds that was thought to interact with a specific endogenous
component of neurons and contributed to the development of receptor theory. Indeed,
more is known about the molecular morphology of the nicotinic cholinergic receptor than
any other receptor. The antagonists of nicotine have been crucial for the development of
nicotine's phannacology and in the classification of peripheral and central nicotinic
receptors. The effects of nicotine that are attenuated by nicotinic antagonists are attributed
to nicotinic cholinergic receptors, however evidence is being accumulated that suggests
that the antagonists may not be acting directly at the receptor. Little is known regarding
the events that lead to the phannacological effects of nicotine subsequent to receptor
binding, and even less is known regarding the mechanism of action of the antagonists in
the CNS. A greater appreciation of the mechanism of action of nicotine in the eNS can be
obtained by investigation of the antagonists.
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B. Tobacco Vse and Nicotine
The fIrst record of tobacco use is a Mayan stone carving dated at

600

to

900

A. D.

(U.S. Dept. of Health and Human Services, 1988). The use of nicotine through the
smoking or chewing of leaves from the Nicotania

tabacum

and N.

rustica

plants was

introduced into various European countries by sailors returning from voyages in the New
World in the mid 1 500's. The genus Nicotania was named after the French ambassador
to Lisbon, Jean Nicot, who is said to have sent the

seed

of N.

tabacum

to the queen

consort and regent of France, Catherine de Medicis (Encyclo. Britannica, 1985). Nicot
also touted tobacco as a cure-all throughout Europe in the late 1500's ( V.S. Dept. of
Health and Human Services, 1988).

Before its commercial cultivation began in

Jamestown, Virginia in 1 612, tobacco had been introduced into all parts of the known
world, including Russia and Japan.

In

1619, the production of tobacco had become so

commercially successful that the crop was used not only to barter for goods, but also to
pay taxes and for the salaries of public officials. Furthermore, the profit margin of
tobacco production became so great that in 162 1 , production limitations had to be imposed
in order to increase the production of food crops in the English colonies (Encyclo.
Americana, 1987).
Tobacco use increased greatly in the following years. Following the development of
the cigarette shortly after the Civil War and of blended tobacco in the 1 9 1 0's, the
processing and production of fmished products from tobacco became a tremendously
successful industrial enterprise (V.S. Dept. of Health and Human Services, 1988). From
1930 to 1940, an average of 347 billion pounds of manufactured tobacco and 1 48 billion
cigarettes were produced per annum by V. S. companies. Despite growing concerns over
the adverse health effects of tobacco use, per capita consumption of tobacco in the Vnited
States increased from 9.62 pounds in 1940 to 1 1 .82 pounds in 1960 (U. S. Bureau of the
Census, 1 967). Although per capita consumption of tobacco products in the V. S. was
down to 6.9 pounds in 1984, the tobacco industry produced 657 billion cigarettes and 4.5

3
billion cigars in the United States alone. The value of all tobacco products produced in the
United States in 1984 was over $17 billion (U. S. Bureau of the Census, 1987).
Due to the prevalence of tobacco use in the world, research began in the early 1800's to
identify the constituents of tobacco that contribute to its habitual use. An oily substance
was isolated from tobacco by Cerioli and Vanquelin in the early 1800's and was named
"Nicotianine". This substance was further purified and renamed "Nikotin" by Posselt and
Reiman in 1828. The empirical formula of this substance was elucidated in the 1840's and
nicotine was flrst synthesized in the 1890's ( U.S. Dept. of Health and Human Services,
1988). Since then, numerous investigators have sought to determine the role of nicotine in
tobacco use.
The evidence in support of nicotine being the principal component of tobacco that
contributes to its habitual use is a culmination of chemical and biological data on the
constituents of tobacco smoke, their absorption into the blood and distribution into the
brain, and their effects on humans and laboratory animals. An extensive review of this
subject is provided in The Health Consequences of Smokin�; Njcotine Addiction a report

of the SUT�eon General (U.S. Dept. of Health and Human Services, 1988). Nicotine has
been found to be the primary alkaloid present in tobacco smoke (Piade and Hoffman,
1980) and Benowitz et aI. (1987) have shown that nicotine enters the bloodstream
following tobacco use. Furthermore, peak blood concentrations are similar following the
use of a variety of tobacco products (Benowitz, 1987). Given free access to tobacco,
smokers have been shown to rapidly achieve a blood level of nicotine in the morning
hours that remains steady throughout the day (Benowitz et aI"

1982).

Earlier,

Schmiterlow et al. (1967) had shown that nicotine was readily distributed into the brains
of mice and cats following Lv. administration. Other researchers have found this to be
true for mice (StAlhandske, 1970, Maziere, et aI., 1976), rats (Oldendorf, 1974), and
rabbits (Maziere, et al.,1976).

Therefore, based on these studies and others, nicotine has

been shown to enter the bloodstream and, consequently, the brain following tobacco use.
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Nicotine possesses pharmacological properties that are consistent with other drugs of
abuse. Drugs of abuse have been shown to be positive reinforcers in humans and animals
(Thompson and Unna, 1977; Thompson and Schuster, 1968). Nicotine has been shown
to be a positive reinforcer in beagles (Risner and Goldberg, 1983), squirrel monkeys
(Goldberg and Spealman, 1983), rhesus monkeys (Yanagita, 1977), and humans
(Goldberg and Henningfield, 1983; Henningfield et al., 1983). Nicotine has been shown
to be an even more effective secondary reinforcer, where drug administration is associated

with an external cue (Goldberg et aI., 1981; Spealman and Goldberg, 1982).
Mecamylamine antagonized both the primary (Goldberg and Spealman, 1982) and
secondary (Goldberg et al., 1981; Spealman and Goldberg, 1982) reinforcing properties
of nicotine. Furthermore, nicotine administration decreases smoking in human subjects
whether administered i.v. (Lucchesi et al., 1967; Henningfield et al. , 1983) or p.o. in the
form of capsules (Jarvik et al., 1970) or gum (Nemeth-Coslett, et al., 1987; Russell, et
al., 1976). Conversely, mecamylamine increases cigarette smoking (Stolerman et al.,
1973a; Nemeth-Coslett et al., 1986; Pomerleau et al., 1987). Pentolinium, which does
not cross the blood-brain barrier, has no effect on cigarette smoking, suggesting that
nicotine acts centrally to reinforce smoking behavior , and that mecamylamine's
antagonism is centrally mediated (Stolerman et al., 1973a). Cessation of chronic nicotine
intake has also been shown to produce a characteristic withdrawal syndrome (American
Psyhciatric Association, 1987). These data suggest that smoking is a means of obtaining
nicotine in order to experience its reinforcing properties or prevent withdrawal effects.
C

Phannaco!o� of Nicotine

1.

Physiolo�cal Responses and Behavioral Effects
Investigations of nicotine's pharmacology have sought to answer other questions which

are not related to tobacco use, but rather to characterize the nicotinic cholinergic system.
Nicotine produces a myriad of effects when administered to animals which are peripherally
mediated, centrally mediated, or a composite of both. Nicotine was fIrst demonstrated to
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act at autonomic ganglia by Langley and Dickinson in 1889. Dale (1905) demonstrated
that acetylcholine had nicotinic and muscarinic components that could be separated.
Peripherally, nicotine's effects can be largely explained by its actions on the
sympathetic and parasympathetic ganglia, where transient stimulation by nicotine is
followed by a more prolonged blockade. Nicotine has a biphasic effect on the release of
catecholarnines from the adrenal medulla and on stimulation of skeletal muscle. In the
latter tissue however, the stimulant effect is largely masked by a more prolonged
relaxation.

Nicotine also stimulates a number of sensory receptors that include

mechanoreceptors of the skin, tongue, lung, mesentery, and stomach; as well as
chemoreceptors in the carotid body, thermal receptors of the skin and tongue, and pain
receptors. Hexamethonium has been found to antagonize these actions. Composites of
the ganglionic effects lead to tachycardia and hypertension, increased gastrointestinal
motility and tone in the gut, and increased salivary and bronchial secretions. Nicotine
causes nausea and vomiting as a result of stimulation of sensory nerves in vagal and spinal
afferents in combination with stimulation of chemoreceptors in the area postrema of the
medulla (Taylor, 1985).

Nicotine also stimulates respiration due to activation of

chemoreceptors in the carotid bodies as well as direct stimulation of central respiratory
centers at higher doses.

Stimulation is followed by respiratory depression due to

desensitization of the central respiratory centers of the brainstem and neuromuscular
blockade of respiratory muscles (Westphal,

1982).

In the CNS, nicotine has an intriguing profile of pharmacological effects which has
been reviewed in detail (Martin,

1986).

As in the periphery, both stimulation and

depression occur. As mentioned above, nicotine can cause nausea and vomiting due

to its

stimulatory actions on the area postrema of the medulla oblongata. Other stimulatory
effects include tremors, convulsions, and release of antidiuretic hormone from the pituitary
(Westphal, 1982). Nicotine has been found to cause EEG activation (Longo et aI., 1954;
Rinaldi and Himwich, 1955) which may be mediated in part by peripheral afferent C fibers
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(Ginzel, 1987; Murphree et aI., 1967).

In addition to the effects mentioned above,

nicotine has been shown to cause antinociception (Phan, et aI., 1973; Sahley and
Berntson, 1979; Tripathi, et al., 1982) and alterations in behavior and leaming (Larson, et
al., 1961; Iwamoto, et al., 1987). Nicotine has been shown to depress activity in rodents
(Morrison, 1969; Martin, et aI., 1983). A review by Hall (1984) describes temperature
regulation, sleep and arousal, release of coricosteroids, and water intake as effects of
intracerebrally administered nicotine.

Nicotine has also been found to possess

discriminative stimulus effects in the CNS (Stolerman, et aI., 1987; Morrison and
Stephenson, 1969; Rosecrans and Chance, 1978), some of which may not be cholinergic
(Rosecrans and Chance, 1977; Rosecrans, 1987). Ganglionic blockers that penetrate the
CNS, such as mecamylamine, have been shown to antagonize most, if not all, of
nicotine's central effects (Martin, 1986; Stolerman et al., 1983).

2. Effects of Nicotine on Neurotransmitter Release
Numerous investigators have attempted to attribute the behavioral effects of nicotine to
its actions on the release of neurotransmitters in the CNS. Extensive reviews on this
subject are available (Aceto and Martin, 1982; Balfour, 1982; Rowell, 1987;

U.

S. Dept.

of Health and Human Services, 1988). Nicotine has been shown to stimulate the release
of norepinephrine

(NE),

dopamine (DA), serotonin (5-HT) and acetylcholine (ACh)

(Rowell, 1987). The specific behavioral effects associated with each of these various

neurotransmitters remain s unclear, however.
Nicotine stimulates the release of catecholamines in various brain regions by two
distinct mechanisms; one that is calcium dependent and occurs at lower doses, and one that
is not calcium dependent and is similar to the release seen by tyramine. The first process
occurs with adrenergic nerve terminals in the hypothalamus as shown with both slices and
synaptosomes. Norepinephrine

(NE)

released in response to nicotine in other brain areas

appears to be due to displacement from storage vessicles in that it is calcium-independent
and occurs only at doses greater than 10 JlM (Balfour, 1982). Nicotine indirectly affects
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NE release in the locus coeruleus, an important NE-containing nucleus. Peripherally
administered nicotine stimulates the locus coeruleus, whereas microiontophoresis of
nicotine onto this structure has no effect (Svensson and Engberg, 1980). Mecamylamine
has been shown to be an effective antagonist of nicotine's actions on NE release in the
brain (Balfour, 1982).
The effects of nicotine on brain DA release and turnover has been studied less
extensively. Nicotine also increases DA release in striatal slices that is abolished by
pempidine or the omission of calcium (Giorgiueff-Chesselet et al., 1979). Nicotine has
also been shown to increase DA release in vivo in the striatum (Giorgiueff-Chesselet et
al., 1976) and in the nucleus accumbens (Misfud et al., 1989). Nicotine has been shown
to increase DA release in the mesolimbic and meso striatal dopaminergic neurons, and it
has been postulated that some of the euphoric effects of nicotine may be mediated by these

systems. Nicotine appears to modulate neuroendocrine effects through both NE and DA
release, with noradrenergic neurons being involved in the control of the
hypothalamic-pituitary-adrenal-axis, and dopaminergic neurons inhibiting the release of
prolactin, LH, FSH, and TSH (Fuxe et al., 1987).
Nicotine appears to have little effect on the serotonergic system in the CNS. This
aspect of nicotine's pharmacology has not been studied extensively, however. Nicotine
has been shown to reduce the turnover of S-RT in the hippocampus and reduces the
capacity of hippocampal synaptosomes to accumulate L-typtophan.

These changes

ocurred only after chronic administration of nicotine and were produced by cotinine,
nicotine's major metabolite, as well. Furthermore, these effect�e� n� antagonized b y
_

mecamylamine (Aceto and Martin, 1982; Balfour, 1982).
Nicotine has been shown to affect ACh release as well.

Armitage et a1. ( 1968)

demonstrated that nicotine would increase the release of ACh from the parietal cortex,
whereas higher doses decreased release. Cortical EEG activation and inhibition followed
the stimulated and reduced ACh release, respectively. Morrison (1968) postulated that
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ACh release was involved in the depressant effects of nicotine on bar-pressing for water
reward in that physostigmine, at doses that had no effect by themselves, poteniated this
effect of nicotine. Neostigmine, which does not penetrate the CNS, had no effect.
Armitage et al. (1966) have likewise shown that nicotine would induce an ear-twitching
response in cats that was associated with central ACh release, in that physostigmine
potentiated this response as well.
D. The Njcotinic Cboljner�c Receptor

Peripheral Njcotinic Receptors
The concept of a nicotinic receptor evolved over the past century. In 1889, Langley
and Dickinson demonstrated that nicotine exerted a direct effect on the gangljon. Langley

also postulated the existence of a "receptive substance" for nicotine and, in 1914 reported
that curare would block nicotine's actions on skeletal muscle (Langley, 1905; Langley,
1914). Dale (1914) found that acetylcholine had effects that could be separated into two

components, one mimicked by muscarine and the other by nicotine. The existence of
muscarinic receptors at parasympathetic effector sites and of nicotinic receptors at the
neuromuscular junction, adrenal medulla, and at both the sympathetic and parasympathetic
ganglia is now fully appreciated. The use of specific antagonists has resulted in the
classification of ganglionic and neuromuscular nicotinic receptors as distinct subtypes
based upon the number of carbon atoms in the chain that attaches the two amino groups
that results in optimum antagonistic activity.

Attempts to isolate this receptor from

peripheral tissues met with little success until the discovery of a-bungarotoxin and toxins
from other elap id snakes that bind with high affinity to the peripheral nicotinic receptor
(Aceto and Martin, 1982). A glycosidic protein has been isolated from electric eel and
fi sh, as well as from mammalian muscle, that binds nicotine and acetylcholine
(Conti-Tronconi and Raftery, 1982). The extensive biochemistry that has been done on
this protein will be reviewed later.
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2.

Central Nicotinic Rec<:ptors

a

PharmacoJQdca! Eyjd<:nc<:
The existence of central nicotinic receptors was postulated due to the fact that nicotine

produced behavioral effects that were antagonized by ganglionic blockers. As mentioned
previously, nicotine produces a myriad of central effects that are antagonized by
mecamylamine, a ganglionic antagonist that penetrates the CNS.

Antagonism of the

effects of nicotine has also been seen by a number of investigators following central
administration of hexamethonium. These effects include hypotension (Armitage and Hall,
1967; Feldberg and Guertzenstein, 1976), hypothermia (Hall, 1972), salivation (Hall and

Reit, 1966) and motor reflexes (Hall and Reit, 1966).

These observations led

investigators to postulate the existence of a central nicotinic receptor of the C6 type.
However, other investigators have shown that dihydro-B-erythroidine will antagonize
nicotine centrally, suggesting the existence of CIO nicotinic receptors in the CNS as well
(Bradley et al., 1699; Bradley and Dray, 1976; Bradley and Lucy, 1979). Aceto et al.
(1969) demonstrated that nicotine-induced convulsions were blocked by the ganglionic

blockers cblorisondarnine, pentamethonium, mecamylamine, and hexamethonium, but not
by atropine, chlorpromazine, morphine, or phenobarbitone. It has been found by a
number of investigators that the only compounds that block the nicotine cue in drug
discrimination are those that block nicotine's effects at autonomic ganglia and penetrate the
CNS (Stolerman et al., 1987). It is interesting to note that chlorisondarnine, a quaternary
ganglionic-blocking agent, antagonizes the nicotine cue when given centrally (Garcha et
al., 1985) but not peripherally (Romano et al., 1981). Therefore, these antagonists have
proven invaluable for the characterization of central nicotinic recepors pharmacologically.
Other pharmacological evidence for the existence of a nicotinic receptor in the CNS
comes from studies on the stereoselectivity of nicotine. It has been shown that the
naturally occuring isomer, (-)-nicotine, has a similar pharmacological profile as the
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unnatural (+)-nicotine. Studies of the central activity of these compounds by a number of
investigators has revealed that (- )-nicotine is only I to 25 times more potent than
(+)-nicotine in most assays for central nicotinic activity (Martin,1986).

It has been

postulated that this low degree of stereose1ectivity is due to the flexible nature of nicotine
and that the nin;?gen atoms of (+)- and (-)-nicotine can be superimposed using molecular
models (Aceto e� aI., 1984). Attempts to construct conformationally restricted analogs that
retain pharmacological activity has been unsuccessful thus far (Martin, 1986).
Using drug discrimination, several investigators have demonstrated structural
requirements for nicotinic activity. Chance et al.

(1978) found that of a number of analogs

tested, only 3-pyridylmethylpyrrolidine generalized to nicotine. An intact pyrrolidine ring
appeared to be necessary for activity and increasing the distance between the pyridine and
pyrrolidine rings decreased potency. Rosecrans et al.

(1978) showed that nomicotine and

cotinine were less potent than nicotine. Furthermore, Garcha et al. (1982) demonstrated
that cytisine produced nicotine-like responding to a nicotine cue. Sto1erman et al. (1987)
showed that cytisine and anabasine generalized to the nicotine cue, although they were less
potent than nicotine.

Cytisine given i.c.v. has also been found to induce changes in

locomotor activity in rats, an effect that was antagonized by mecamylamine (Pert and
Clarke, 1987).

Rosecrans et al.

(1978)

showed that nicotine-trained animals did not

generalize to a quaternary analog of nicotine, supposedly due to its inability to enter the

brain. The nicotine cue has been found to be selective in that neither

arec oli ne

(Me ltzer

and Rosecrans, 1981), picrotoxin, nor chlordiazepoxide (Stolerman et al., 1987)
generalize from nicotine in nicotine-trained animals. Therefore, there appears to be
structural requirements for nicotine's central effects.

b

Radioli�and Bindin� Studies
Early attempts to characterize nicotinic receptors in vitro utilized a number of

radiolabelled cholinergic ligands other than nicotine due to the lack of availability of
radiolabelled nicotine of high specific activity (Martin, 1986). Eldefrawi et al. (1970)

11

studied 3H-muscarone binding to housefly brain. These investigators were not able to
elucidate a high affinity binding site and interpretation of the binding regarding its
relevance to nicotine was difficult due to the mixed nicotinic and muscarinic properties of
muscarone. Early studies with radiolabelled tubocurarine and decamethonium likewise
met with little success as binding to rat brain tissue was found to be of low affinity
(Eldefrawi et al., 1970). High affinity binding sites have been found for 3H-tubocurarine
in rat hippocampus, suggesting the existence of CIO type receptors in the CNS (Nordberg
and Larsson , 1980). Two sites with Kd's of 1.5 and14 nM were reported and nicotine
was found to be 50 times more effective than tubocurarine in competing for the
high-affinity binding. Schwartz et al. (1982) studied 3H-acetylcholine binding to rat brain
and

was able to elucidate a high affmity site in the presence of diisopropylfluorophosphate

and atropine. This binding was found to have a Kd of 12 nM and a Bmax of 4.6 pmoles/g
tissue. Nicotinic agonists were found to compete effectively for this binding, whereas
decamethonium and mecamylamine were 3 and 5 orders of magnitude less potent than
(-)-nicotine, respectively. It has been subsequently shown that the autoradiographic
distribution of 3H-nicotine and 3H-ACh in the presence of atropine to mammalian brain are
vitually identical (Clarke et al., 1985a).
The use of a-neurotoxins to label central nicotinic sites met with popularity in the
1970's and early 1980's due to their high affinity for peripheral nicotinic receptors and the
belief that peripheral and central nicotinic receptors were similar. It has been shown that
the affinity of a-neurotoxins for peripheral and central binding sites are similar (Oswald
and Freeeman, 198 1 ) .

Nicotinic receptors partially purified from rat brain and

electroplaque tissue using affinity chromatography with a-neurotoxins display similar
chromatographic properties as well (Salvaterra and Mahler, 1 976).

However,

investigators have found that a-bungarotoxin is without activity at central and autonomic
synapses (Chou and Lee, 1969; Duggan et al., 1976; Ko et at, 1976; B rown and
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Fumagalli, 1 977; Patrick and Stallcup, 1 977; Misgeld et al., 1 980). Furthermore,
nicotinic agonists and antagonists do not compete for this binding with high affinity
(Salvaterra and Mahler, 1 976; McQuarrie et al., 1 976; Schmidt, 1 977; Moore and Brady,
1 977; Morley et aI., 1 977; Ben-Barak and Dudai, 1 979; Block and Billiar, 1 9 8 1 ) .
Autoradiograms o f 3H-nicotine an d 3H-a-bungarotoxin binding to brain reveal unique
distributions of binding sites for these ligands as well (Clarke et al., 1 985a). It has been
shown that a-bungarotoxin binding sites can be physically separated from high-affinity
nicotine binding sites using affinity chromatography with a-bungarotoxin as the affinity
reagent (Wonnacott, 1 986). Nicotine was found to compete for a-bungarotoxin binding
to the protein retained on the column only at micromolar concentrations (Wonnacott,
1986). Whiting and Lindstrom (1988) have proposed the existence of a nicotinic receptor
family based upon the purification and cloning of nicotinic receptors from a variety of
tissues, including mammalian brain. It has been shown that the peripheral and central
nicotinic receptors are quite different in several salient structural features (Whiting et al.,
1 987). Therefore, the relevance of central a-neurotoxin binding sites to nicotine's
pharmacology is questionable.
The availability of radiolabelled nicotine with high specific activity in the late 1 970's
and 1980's greatly enhanced investigations of central nicotinic binding sites. The binding
of 3H-nicotine to rat brain has been found to be saturable and dependent upon temperature,
time, and pH of the incubation medium (Martin and Aceto, 1981). Due to variations in the
techniques used, there is a discrepancy in the literature for affinity constants for
3H-nicotine binding to brain, ranging from 0.2 to 590

nM

(Martin, 1 986). However,

binding sites for nicotine with a Kd in the low nM range have been demonstrated in the
brains of mice (Marks and Collins, 1 982), rats (Romano and Goldstein, 1 980), monkeys
(Friedman et al., 1 985), and humans (Shimohama et al., 1 985; Flynn and Mash, 1 986;
Whitehouse et al., 1 986).
There is also a lack of consensus regarding the existence of multiple binding sites and
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the stereo selectivity of 3H-nicotine binding to brain (Martin, 1 986). The number of
distinct nicotinic binding sites in the CNS varies from one (Marks and Collins, 1 982) to
four (Sloan et al., 1 984). It has been suggested that the low-affinity sites arise from
proteolytic degradation of the high affinity site (Lippiello and Fernandes, 1 986). The ratio
of the ICso of (+)- to (-)-nicotine in displacing 3H-(±)-nicotine binding to brain tissue
varies from 3 to 63 (Martin, 1 986). A direct comparison of the binding properties of the
separate enantiomers of 3H-nicotine by the same laboratory revealed that the binding
characteristics of 3H-(+)- and (-)-nicotine were similar, differing only in their affinity
constants. The dextrorotatory antipode was found to posses three-fold less affinity for the
binding site than its levorotatory counterpart (Vincek et al., 1 98 1 ). Subsequent binding
studies of the displacement of 3H-(-)-nicotine by (+)- and (-)-nicotine were consistent with
this study (Vincek et

aI.,

1 980; Sershen et al., 1 98 1 ; Sloan et al., 1 983; Abood et aI.,

1 983). These findings are consistent with the low stereoselectivity of nicotine's
pharmacological effects, as mentioned previously.The existence of noncholinergic
nicotinic binding sites in brain has been supported by the work of Abood et al.(1 980).
They have been able to elucidate saturable nicotine binding with high affinity that is not
displaced by cholinergic ligands. Other investigators have postulated noncholinergic
effects of nicotine in the brain, supporting the notion of nicotine binding sites that may be
noncholinergic. Regardless of the cholinergic or noncholinergic nature of the nicotine
binding sites that have been elucidated to date, it has been shown that none of the nicotinic
antagonists compete for in vitro 3H-nicotine binding to brain (Martin, 1 986). Romano
and Goldstein ( 1 980) have suggested that the long incubation used causes an
agonist-induced shift of the conformation of the receptor to an antagonist-insensitive form.
Marks and Collins (1 982) have postulated that the agonists and antagonists bind to distinct
receptors. Binding studies with radiolabelled antagonists that address these issues have
not been documented to date.
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3. Biochemical Characterization of the Nicotinic Rece,ptor
The molecular structure of the nicotinic acetylcholine receptor-ionophore complex
(nAChR) from electric eel and fish organs has been studied extensively. An excellent
review of the literature has been provided by Conti-Tronconi and Raftery ( 1 982). The
nAChR has been purified from extracts of the electric organs of a number of species of
fish and eel as well as from marnma1ian muscle using affinity chromatography with either
cholinergic ligands (Schmidt and Raftery, 1 972; Olsen et al., 1 972) or a-neurotoxins
(Raftery, 1 973; Karlsson et al., 1 972). This molecule represents the first neurotransmitter
receptor to be isolated, purified, and reconstituted into membranes with retention of its
physiological properties. This macromolecule is a glycosidic protein consisting of four
distinct subunits, termed a, B,

y,

and li, with a final stoichiometry of a2Byli.

The

biochemical characterization of these subunits is beyond the scope of this discussion, but it
suffices to note that there is considerable homology between the subunits from different
fish and eel, as well as mammalian muscle. These five subunits form a rosette-like
macromolecule with a central pore that is 15 to 25 A in diameter. Each of the subunits
traverse the membrane several times. Upon depolarization of the membrane, either by
receptor agonists or electrical stimulation, the pore opens and the ionophore allows cations
to pass through the pore. Anions do not flow through the pore due to a large number of
negatively charged moieties at the pore entrance (Conti-Tronconi and Raftery, 1 982).
Using monoclonal antibodies generated from electroplax, Conti-Tronconi et aI. ( 1 985)
isolated a nicotinic receptor from the chick optic lobe and muscle. The central receptor
was found to possess some homology to the muscle receptor, but displayed significant
differences in subunit molecular weights as well. Barnard et

aI.

( 1 980) found that

nicotinic receptors isolated from the chick optic tectum in this manner possessed only two
distinct subunits, whereas the muscle and electroplacque receptors are found to possess
five.
Whiting et aI. (1987) have used immune-affinity techniques to purify and clone putative
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nicotinic receptors from chick and rat brain.

These proteins bind nicotine and

acetylacholine with high affmity, but not a-bungarotoxin. They have found that only two
distinct subunits exist for this protein and the a subunit is nearly identical for the brain and
muscle receptors. Conversely, the 13 subunit of the central receptor appears to be quite
unique and they have concluded that the central receptor is a distant relative of the
electroplacque and muscle nicotinic receptors. They have also provided evidence that the
stoichiometric ratio of the subunits in the brain nicotinic receptor is a 3 132. The
autoradiographic pattern of localization in rat brain of the monoclonal antibodies that these
investigators used to purify and clone this receptor is nearly identical to that of nicotine and
acetylcholine (Swanson et a1., 1 987). Therefore, it is apparent that the neuromuscular and
central nicotinic receptors are quite different, but their relationship to the ganglionic
receptor is unknown.
4 Functional Si�njficance of Central Nicotinic Bindin� Sites

Evidence that the binding sites elucidated in brain for nicotine have pharmacological and
physiological relevance consists primarily of studies comparing the selectivity,
structure-activity relationships, and localization of these binding sites in the brain to
nicotine's central pharmacological effects.

The selectivity and structure-activity

relationships for the discriminative effects of nicotine has been discussed earlier. The
ability of nicotine, cytisine, and anabasine to generalize to the nicotine cue in rats is well
correlated with their ability to displace 3H-nicotine binding to brain tissue (Marks and
Collins, 1 982; Romano and Goldstein, 1 980; Scimeca and Martin, 1 988). As mentioned
above, the stereoselectivity of nicotine in displacing 3H-(-)-nicotine binding to brain is
consistent with its low degree of stereoselectivity in producing central pharmacological
effects.

Muscarinic compounds have not been found to compete effectively for

3 H-nicotine binding to brain tissue, demonstrating that nicotine binding to brain is
selective for nicotinic compounds (Marks and Collins, 1 982; Romano and Goldstein,
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1980; Scimeca and Martin, 1 988).
The central distribution of 3 H-nicotine binding sites in brain has been studied
extensively using quantitative receptor autoradiography. These studies have revealed that
3 H-nicotine binds to brain slices with a discrete pattern of localization. The greatest
number of nicotinic receptors have been found in the thalamus, interpeduncular nucleus,
cortex, superficial layer of the superior colliculus, and medial habenula, whereas the
hippocampus, hypothalamus, and reticular formation possess relatively few nicotinic
receptors (Clarke et al., 1 985a; Segal et al., 1 978; Duggan et al., 1 976). This pattern has
been found to be strikingly similar to the autoradiographic localization of nicotine's
metabolic effects in brain through 2-deoxyglucose utilization studies (London et al.,
1 985). These investigators have found that mecamylamine would completely antagonize
nicotine's effects on the metabolic activity of central neurons. Therefore, the binding sites
for nicotine are not uniformly distributed in brain and nicotine's ability to increase the
metabolism of neurons in a particular brain area is well correlated with the presence of
nicotine binding sites. This suggests that these binding sites are relevant to the
pharmacological effects of nicotine.
E. Nicotinic Antagonists
1. History
Nicotinic antagonists have served to define and delineate the various nicotinic
cholinergic systems in mammals. Their role can be readily appreciated by the previous
discussion of nicotine's pharmacology and of nicotinic binding sites found in a variety of
mammalian tissues, as well as electric organs of fish and eel. The remainder of the
discussion will focus on the antagonists themselves with respect to their mechanism of
action on the various effects of nicotine and their relevance to nicotinic binding sites.

In

1 956, Stone et al. reported that a tertiary amine, 3-methylaminoisocamphane, termed
mecamylamine, was found to possess potent ganglion-blocking activity. Prior to this,
most potent ganglion-blocking agents were quaternary amines of quick onset and short
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duration of action. Most tertiary amines that had demonstrated ganglion-blocking
properties at that time either possessed other pharmacological properties or had low
potency (Stone et al 1 956). However. these investigators found that mecamylamine was
.•

potent and had a longer duration of action that was slower in onset than the classical
quaternary amino compounds. They concluded that such a compound had therapeutic
potential as an antihypertensive. Spinks and Young fIrst described the ganglion-blocking
properties of a series of polyalkylpiperidines in 1 95 8 and found that
1 .2.2.6.6-pentarnethylpiperidine had the greatest potency of all tested and termed the
compound pempidine. They demonstrated that pempidine was approximately twice as
potent as mecamylamine and yet had an LDso four- to seven-fold greater than
mecamylamine. depending upon the route of administration.

These investigators

concluded that these compounds had therapeutic potential as antihypertensives. however
the adrenergic antagonists have largely replaced them for this purpose due to their greater
efficacy and therapeutic index (Taylor. 1987).
2

Anta�nism of Nicotine

a Neuromuscular Junction and Electro,plax Tissue
The mechanism of action of nicotinic antagonists at the neuromuscular junction and
electroplax tissue has been studied extensively using a variety of depolarizing blockers and
neurotoxins. This discussion will focus on the studies that have attempted to discern the
relationship between such compounds and the central nicotinic antagonists. such as
mecamylamine and pempidine. Mecamylamine was shown to antagonize contractions of
the frog rectus abdominus muscle induced by octarnethylenebis(carbamylcholine) (B�)
by van Rossum and Ariens ( 1 959) in a noncompetitive manner. They found that
mecamylamine and chlorisondarnine shifted the dose-response curves of B� downward.
unlike a number of bis(quaternaryamino) derivatives that shifted dose-response curves to
the right in a parallel manner. consistent with competitive antagonism. Blackman and Ray
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( 1 964) demonstrated that blockade of muscle twitch i n the rat phrenic nerve-diaphragm
preparation by mecamylamine and pempidine was extracellularly mediated in that
quaternary derivatives of each compound had nearly identical potencies. Using
microelectrode recordings of the potential of cell body membranes of cockroach
motoneurones, David and Sattelle ( 1984) demonstrated that mecamylamine blocked
ACh-induced depolarization in a voltage-independent manner.

This suggests that

mecamylamine is acting on a closed-channel state of the receptor-ionophore complex, in
that increasing the applied voltage (i.e., less negative) increases the number of open
channels. In contrast, blockade by d-tubocurarine decreased with increasing membrane
potential, suggesting open-channel blockade.

Pretreatment with a-cobrotoxin

(a-COTX), a reversible neurotoxin, was found to prevent irreversible blockade of the
motoneurones by a-BTX, whereas mecamylamine pretreatment had no effect on the
reversibility of this blockade, suggesting that its site of action is distinct from that of
a-BTX.
The histrionicotoxins have proven to be useful compounds for the characterization of
the channel of the nAChR found in muscle and electroplax tissue. Histrionicotoxin is an
alkaloid isolated from the skin of Dendrobates histrionicus , a frog native to Colombia.
This compound, as well as its saturated derivative perhydrohistrionicotoxin (H 12-HTX)
has been shown to produce voltage- and time-dependent blockade of neuromuscular
transmission through the nicotinic receptor at the motor end-plate (Albuquerque and
Oliveira, 1 979; Masukawa and Albuquerque, 1 97 8 ) .

Aronstam et a1. ( 1 9 8 1 )

demonstrated that 3H- Hl r HTX binding to electroplax tissue was affected b y the
conformational state of the receptor ionophore complex. They found that cholinergic
agonists increased the initial rate and affinjty of 3H-HI2-HTX binding but had no effect on
the Bmax. It has been shown that cholinergic agonists increase the potency of H l rHTX
in blocking end-plate currents in frog and mammalian muscle (Lapa et al., 1 975). This
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suggests that HI2-HTX binds to a site within the open channel of the nAChR to block ion
flow. However, the binding kinetics of 3H-H12-HTX suggests that there are multiple
binding sites. Further evidence for the existence of multiple binding sites for this
compound is the difference in the ability of carbamylcholine to stimulate the displacement
of 3H-H 1rHTX binding by other compounds. Compounds that interact directly with
ionic channels, such as phencyclidine, compete more effectively for 3H-HI2-HTX binding

in the presence of carbamylcholine, suggesting that 3H - H 1 rHTX binds to
open-channel form of the receptor.

an

Conversely, carbamylcholine has no effect on

compounds that do not bind to sites within the channel, such as tetraethylammonium,
suggesting that 3H-HI2-HTX binds to sites outside of the channel as well (Aronstam et
al. , 1 9 8 1 ) .
The relationship o f mecamylamine t o perhistrionicotoxin antagonism a t the
neuromuscular junction and binding to electroplax has also been investigated. Varanda et
al. ( 1 985) studied the effect of mecamylamine on 3H-H12-HTX binding to electroplax

nAChR. They found that mecamylamine competed effectively for 3H-HI2-HTX binding

to electroplax tissue, but that this interaction was not enhanced by carbamylcholine. This
suggests that mecamylamine may be binding to one of the sites for 3H-H12-HTX outside
of the ionic channel. Mecamylamine was not found to compete effectively for 3H-ACh
binding to this tissue. These investigators also studied the ability of mecamylamine to
block end-plate currents of frog sartorius muscle. They found that mecamylamine
produced a concentration- and voltage-dependent shortening of mean channel open time
and the end-plate current (EPC) peak amplitude. A linear relationship between the
reciprocal of the decay time constant of the EPC and the concentration of mecamylamine
was demonstrated, suggesting open-channel blockade. Single-channel recordings from rat
myoballs demonstrated that mecamylamine did not alter channel conductance or reversal
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potential, but decreased mean channel-open time in a concentration-dependent manner.
Therefore, these studies collectively indicate that mecamylamine noncompetitively inhibits
neuromuscular transmission by binding to an open-channel form of the receptor to
decrease open-channel time and that this binding site is not located within the channel
itself.
b

Gan�lia
The ganglionic-blocking properties of mecamylamine was ftrst described by Stone et al.

( 1 956). These investigators found that mecamylamine was a speciftc antagonist for
nicotinic stimulation of the ganglia. They found that vascular responses in the dog
attributed to autonomic ganglia, such as carotid occlusion and peripheral vagal stimulation,
were antagonized in a dose-dependent manner by mecamylamine.

B oth

acetylcholine-induced hypotension and epinephrine-induced hypertension were potentiated
by mecamylamine, suggesting blockade of compensatory mechanisms through the
ganglia. They further demonstrated mecamylamine's ganglion-blocking effects in the
nictitating membrane of the cat superior cervical ganglion, where mecamylamine blocked
contractions induced by preganglionic electrical stimulation, but not by direct
administration of epinephrine. Mecamylamine was also shown to produce decreases in
mean arterial pressure and heart rate in anesthetized dogs and cats that were qualitatively
similar to quaternary ganglionic-blockers, although slower in onset and longer in duration.
These investigators found that mecamylamine h ad

no

atropine- ,

curarc-,

or

antihistaminic-like activity.
Other ganglion-blocking effects have been documented for this compound, as well as
pempidine.

Bentley and Sabine ( 1 963) found that mecamylamine blocked

electrically-stimulated contractions of the guinea-pig vas deferens at the ganglion and
found no evidence of a bretylium-like action. This finding was corroborated by Clarke
and Capps ( 1 972) in the rabbit ileum. Likewise, mecamylamine and pempidine were
found to decrease gastrointestinal motility in dogs, rabbits, and guinea pigs (Garg, 1966).
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Gokhale e t al. ( 1 967) found that mecamylamine and pempidine potentiated th e actions of
acetylcholine and epinephrine on the iolated rat ileum but totally blocked the actions of
nicotine.

Therefore, these investigations have provided considerable evidence that

mecamylamine and pempidine act directly at autonomic ganglia
Due to the availability of a variety of isolated tissue preparations, the mechanism of
action of these compounds has been studied more intensely at autonomic ganglia than at
any other site. A scheme for the classification of ganglionic blockers was proposed by
van Rossum et al. ( 1 962) following the analysis of the mechanism of a number of
ganglionic-blockers. By analyzing the patterns of the shift of dose-response curves for
nicotinic agonists by these compounds, three distinct categories were found to exist. The
depolarizing blockers are termed class I compounds, and the nondepolarizing blockers are
termed class II and III . Class II compounds are the competitive blocking agents, such as
hexamethonium, and class III compounds are the noncompetitive blocking agents, such as
chlorisondamine. The nicotine dose-response curves for contractions of guines pig
jejunum were shifted downward and to the right by mecamylamine and pempidine. These
compounds were therefore termed class II-III due to the fact that they exhibited the
characteristics of both types of antagonism, with pempidine showing a greater degree of
competitive antagonism than mecamylamine.
Lees and Nishi (1 972) investigated the mechanism of action of mecamylamine on the
rabbit superior cervical ganglion using intracellular recording techniques. They found that

mecamylamine, but not hexamethonium or d-tubocurarine, inhibited post-tetanic
potentiation. Post-tetanic potentiation arises predominately as a result of presynaptic
facilitation of neurotransmitter release, and therefore suggests that mecamylamine
possesses presynaptic actions. By measuring the excitatory postsynaptic potentials of the
neurones in response to a train of stimuli, they found that the fractional release of readily
available ACh was actually increased by mecamylamine, but the amount of ACh readily
available for release was decreased. The net effect of these opposing actions was an
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overall decrease in the release of ACh by a presynaptic stimulus, and the time course of
this effect followed that of inhibition of post-tetanic potentiation.

Interestingly,

mecmaylamine has been shown to have no effect on post-tetanic potentiation of the
neuromuscular junction (Bennett et al., 1957). Lees and Nishi ( 1 972) also demonstrated
that mecamylamine's only effect on the postganglionic fiber was to decrease the excitatory
postsynaptic potentials in response to ACh as it had no effect on membraine excitability or
resting membrane potential.

This was found to be true for hexamethonium and

d-tubocurarine as well. Their conclusions were therefore that mecamylamine had both
presynaptic and postsynaptic effects at autonomic ganglia.
Ascher et al. ( 1 979) studied mecamylamine's antagonism of the parasympathetic
neurones at the rat submandibular ganglion by a two microelectrode voltage-clamp
technique. They found that tubocurarine and hexamethonium produced greater blockade
of agonist-induced currents in the presence of increasing concentrations of agonists. This
blockade was voltage-dependent as well, and the data supported a sequential scheme
whereby these agents bind to the receptor only in an open-channel form. Conversely,
mecamylamine and trimetaphan were found to produce a blockade that was
voltage-independent and decreased with increasing agonist concentration, suggesting that
mecamylamine acts with the closed-channel form of the receptor.
These studies suggest that mecamylamine antagonism at autonomic ganglia occurs by at
least two mechanisms.

Presynaptically, mecamylamine decreases the amount of

acetylcholine release in response to a depolarizing stimulus.

Postsynaptically,

mecamylamine alters the response of the nuerone to acetylcholine. It appears to do this in
a competitive manner, but is clearly different from hexamethonium in its actions in that
mecamylamine favors a closed-channel form of the receptor.
c, Central Nervous System
The mechanism of action of nicotinic antagonists in the

to the

same

brain has not been characterized

extent as in the periphery largely due to the lack of available models and tissue
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preparations for measuring nicotine's central effects. As mentioned previously, nicotine
produces a myriad of central behavioral and biochemical effects that are antagonized by
mecamylamine and pempidine, but neither of these compounds displace in vitro
acetylcholine or nicotine binding to brain tissue. Evidence that mecamylamine is acting
centrally include administration into the brain directly to antagonize nicotine's effects (WU
and Martin, 1 983; Hall, 1972; Armitage et al., 1 966). Hall ( 1 972) also demonstrated that
hexamethonium would mimic mecamylamine in antagonizing nicotine-induced
hypothermia, salivation, and motor reflexes only when administered centrally, as this
quaternary compound does not cross the blood-brain barrier. Furthermore, Stolerman et

al. ( 1 987) using drug discrimination have reported that peripheral nicotinic antagonists that
do not cross the blood-brain barrier do not block the nicotine cue, whereas mecamylamine
is a quite effective antagonist. Mecamylamine has also been shown to antagonize the
hyperpolarization of cultured astrocytes from rat brainstem and spinal cord induced by
nicotine and acetylcholine (Rosli et al., 1988).
S tolerman et al. ( 1 987) studied mecamylamine's ability to block nicotine's
discriminative stimulus effects in an attempt to determine whether mecamylamine acted
competitively or noncompetitively.

The pattern of shift for percent correct lever

responding is similar to the fmdings of van Rossum et al. ( 1962) in the guinea pig jejunum
in that the dose-response curves for nicotine were shifted downward and to the right.
However, the pattern of shift for depression of response

rate was

markedly different in

that the curves were shifted to the right in a parallel manner, suggesting competitive
antagonism. Several aspects of this study make interpretation of the data difficult.
Specific EDso values with corresponding confidence intervals for nicotine at each dose of
mecamylamine were not reported for either effect. There appears to be a lowering of the
maximum effect of nicotine in producing correct lever responding by mecamylamine, but
the statistical significance apparently was not determined. As mentioned previously,
mecamylamine's antagonism of nicotine-induced depression of response rates was
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overcome by increasing the dose of nicotine. This was a confounding factor in that the
maximum dose of nicotine that could be tested to overcome the antagonism of correct lever

responding by mecamylamine was limited by the suppression of response rate, and
evaluation of the data at the higher doses of nicotine is difficult to interpret

3. Structure-activity Relationships
The inability of mecamylamine and pempidine to displace the binding of 3H-nicotine
from brain tissue suggests that they act at a different site than the agonist. However,
binding studies have not been conducted with the antagonists themselves. If these
compounds act at receptors, they should possess structural requirements for activity.
Furthermore, a comparison of the structure-activity relationships of the agonists and
antagonists should provide insights as to the likelihood that they are acting at the same site.
Mecamylamine (N,2,3,3-tetramethyl-2-norbornamine) possesses three chiral centers,
making eight stereoisomers theoretically possible (Figure 1). However, two of the chiral
centers (carbons 1 and 4) are connected by a methylene bridge, limiting the possibilities to
four. The isomers are divided into two groups, namely the exo- and endo-isomers. When

MECAMYLAMINE

Figure 1 . Structures of mecamylamine and pempidine.

PEMPIDINE
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the nitrogen extends away from the carbon cage, the compound is referred to as
(±)-exo-mecamylamine. When the nitrogen is beneath the carbon cage, the comJX>und is
termed (±)-endo-mecamylamine. The structure-activity relationships of mecamylamine
analogues in antagonizing nicotine-induced convulsions and pupil dilitation in mice was
studied by Stone et al. (1962). Optical isomerism was found to have a minor role in the
activity of these compounds, and mecamylamine was found to be the most JX>tent of all
compounds tested. The methyl groups at the N, 2 and 3 JX>sitions were found to be
necessary for activity. The structural requirements for antagonism of nicotine-induced
convulsions were correlated with ganglionic blockade (r= 0.95), suggesting a similar
mechanism may be involved. These findings led Stone et al. ( 1962) to conclude that
mecamylamine has a specific mechanism, JX>ssibly involving a receptor. Unfortunately,
confidence intervals for the estimated EDso's of each compound were not given and it is
not apparent which changes produce a statistically significant alteration in the activity of
mecamylamine. Furthermore, convulsions induced by nicotine occur at relatively high
doses compared to other central effects and may therefore be a less sensitive assay for
antinicotinic activity.
Bretherick et al. ( 1 959) examined a number of pempidine derivatives in the cat
nictitating membrane. It was found that the nature of the N-substitution was important for
activity. The N-ethyl homologue of pempidine was found to be slightly more potent that
the parent compound. Substitutions that decreased the base strength of the nitrogen
resulted in greatly diminished activity, whereas electron-<ionating groups in this position
enhanced the activity somewhat. Three of the four methyls in the 2- and 6-positions were
required for activity, however substitutions in the 4-position had no significant effect. The
pyrollidine counterpart of pempidine (N,2,2,5,5-pentamethyl pyrollidine) was found to be
less potent than pempidine, and all four methyls in the 2- and 5-positions were necessary
for activity. Double bonds in the 2:3 or 3:4 positions of pempidine, as well as in the 3:4
JX>sition of its pyrollidine counterpart did not significantly alter activity. A noncyclic
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analogue, di-t-butylamine was found to be approximately equipotent with pempidine.
These findings suggest that the base strength of the nitrogen and the substituents of the
adjacent carbons are important for the pharmacological activity of pempidine at the
ganglion.

F Objectiyes
The objective of the research presented in this thesis is to more clearly define the
antagonism of nicotine's effects in the brain by the reversible ganglionic blockers
mecamylamine and pempidine. More specifically, the competitive and noncompetitive
nature of this antagonism is explored. If the antagonists act at the same site as nicotine,
they may be a valuable tool for the determination of the conformational states of the
nicotinic receptor necessary for neuronal activation. If these compounds are found to be
noncompetitive however, they may be useful tools for understanding the biochemical and
metabolic events that lead to the pharmacological effects of nicotine subsequent to receptor
binding.

Therefore, in order to obtain a better understanding of nicotine's central

pharmacology, it is necessary to characterize the interaction of nicotine and central
nicotinic antagonists with the nicotinic receptor.
To determine if the antagonists act at the same site as the agonists, behavioral assays
and radioligand binding techniques were utilized. The competitive or noncompetitive
nature of the antagonism of nicotine by pempidine was assessed using in vivo assays for
nicotine's central effects.

The structure-activity relationship for mecamylamine's

antagonism of nicotine's effects was determined in order to address the possibility that the
antagonist interacts with a receptor and to determine whether these compounds act at the
same

site. The binding of rHJ-L-nicotine and rHJ-pempidine was characterized in vitro

and in situ to brain tissue. Quantitative autoradiography was also utilized to determine the
interaction between these compounds. By studying this interaction in vivo and in vitro
one may be able to better delineate between competitive and noncompetitive anagonism of
nicotine by these compounds.

II. Phannacological Characterization of the Interaction in vivo Between
Nicotinic Agonists and Antagonists

Introduction
Central nicotinic antagonists have yet to be fully characterized regarding the competitive
or noncompetitive nature of their antagonism of nicotine using in vivo assays for nicotine's
behavioral effects. The study by Stolerman et aI. ( 1 987) on mecamylamine's antagonism
of the nicotine cue in rats is difficult to interpret for the reasons mentioned previously. The
characterization of the antagonism of other behavioral effects of nicotine by central nicotinic
antagonists may provide insights into this interaction

in vivo

the observation that these compounds do not compete

and determine the relevance of

in vitro

for agonist binding sites.

Nicotine produces a myriad of other central effects, including depression of spontaneous
activity and antinociception, that are antagonized by central nicotinic antagonists.
However, the competitive or noncompetitive nature of these central nicotinic antagonists for
these central effects of nicotine has yet to be documented.
Nicotine has been shown to produce depression of spontaneous

activity in a number of

species. Morrison and Armitage (1967) demonstrated that nicotine produced depression of
spontaneous activity in mice in a dose-dependent manner.

Marks

et

al. ( 1 9 86)

demonstrated a similar effect in four different mouse strains. Morrison and Stephenson
( 1 972) demonstrated that rats became tolerant to this effect of nicotine when administered
daily (0.8 mg/kg) for 4 days and that locomotor activity actually increased after 7 days.
Using a Y-shaped runway, Stolerman et aI. (1973) demostrated that acute and chronic
27
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tolerance developed to nicotine's depressant effects in rats. �t has been shown that acute
administration of nicotine will produce an initial depression of spontaneous activity which
is followed by stimulation (Clarke and Kumar, 1983; Clarke and Kumar, 1983a; Morrison
et aI., 1 969). Chronic administration of nicotine has been shown to produce a stimulation
of locomotor activity (Clarke and Kumar, 1983; Clarke and Kumar, 1983a; Morrison et aI.,

1 969). Both acute and chronic effects of nicotine on locomotor activity are dose-dependent
and are antagonized by mecamylamine, but not hexamethonium, suggesting that this effect
is centrally mediated.
Nicotine has been shown to produce antinociception centrally as well. Mattila et aI .

( 1 968) showed that nicotine had antinociceptive activity in mice and rabbits, and that this
effect was antagonized by mecamylamine but not altered by physostigmine, atropine, or by
reserpine pretreatment. Phan et al. ( 1 973) showed that mecamylamine would antagonize
nicotine-induced antinociception in the hot-plate test in mice and rats . Sahley and Berntson

( 1 979) found that mecamylamine, but not hexamethonium, would antagonize
nicotine-induced antinociception in mice using the tail-flick assay, and that nicotine's effect
was greatly enhanced by central administration, suggesting a central site of action.
Kamerling et aI. ( 1982) found that nicotine given Lv. produced antinociception in the dog
as measured by a skin-twitch response to a heat stimulus that was not antagonized by
naltrexone. The potency of nicotine was enhanced by central administration. Using the
tail-flick assay, Tripathi et al. (1 982) found that 3 mg/kg of nicotine s.c. produced
antinociception in mice that was maximal after 5 min. Furthermore, the time course for this
effect was well correlated with nicotine brain levels. Aceto et aI. ( 1 983) demonstrated that
nicotine, but not its quaternary methiodide derivatives, produced antinociception in rats and
mice. Mecamylamine was found to antagonize nicotine, but hexamethonium was without
effect. These investigations therefore suggest that nicotine produces antinociception
centrally that is antagonized by central nicotinic antagonists.
Since nicotine-induced alterations of locomotor activity and antinociception are
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selectively antagonized by central nicotinic antagonists, these compounds are thought to
have a specific mechanism of action. Although this antagonism is thought to involve
nicotinic receptors, direct evidence is lacking.

Pharmacological criteria for a

receptor-mediated mechanism of action includes structure-activity relationships. Although
extensive studies of this nature have been conducted in the periphery, the structural
requirements for antagonism of the behavioral effects of nicotine have yet to be thoroughly
documented (Stone et aI., 1 962; Bretherick et aI. , 1 966).

Studies addressing the

structure-activity relationships for nicotine in producing its behavioral effects suggests that
stereoisomerism plays a minor role and that an intact pyrollidine ring is necessary (Martin,
1986). Comparisons of the structural requirements for nicotine agonists and antagonists,
as well as analysis of the structural overlap of these compounds wiII yield insights as to the
plausability that an antagonist binding site exists and that the agonists share this binding site
in vivo .

In order to determine

the nature of the antagonism of nicotine by pempidine, the ability

of pempidine to alter the dose-response relationships of nicotine in producing depression of
spontaneous activity and antinociception in mice was determined. Dose-response curves
for nicotine were determined in the presence of increasing doses of the antagonist and
evaluated for differences in the EDso's and the maximum effect produced by nicotine at
each dose of pempidine. In addition the structural requirements for mecamylamine's
antagonism of these effects of nicotine were determined by comparing the potency of
several mecamylamine analogs to the parent compound.

Materials and Methods
�
Male ICR mice (Dominion Laboratories, Dublin, VA) weighing 24-30 g were used for
all test procedures, and a minimum of 1 2 mice were utilized for each dose and time point.
Mice were maintained on a 1 2-hr light/dark cycle and had free access to Purina Rodent
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Chow (Ralston Purina, St. Louis, MO) and water.

�
L-Nicotine bitartrate was synthesized by Dr. Everette L. May (Virginia Commonwealth
University). Pempidine was purchased from Sigma Chemical Co. (St. Louis, MO) and
was converted to its tartrate salt. Mecamylamine HCI was a gift from Merck, Sharp and
Dohme & Co. The mecamylamine analogs were synthesized by Drs. Everette L. May and
John Suchoki (Virginia Commonwealth University). All drugs were administered in 0.9%
NaCI, pH=7.4 as mg free base/kg body weight in a volume of 10 ml/k:g body weight.
Experimental Procedures
Mice were placed into individual photocell activity cages (28 x 1 6.5 cm) immediately
after sc administration of either 0.9% saline, pH =7 .4 or nicotine bitartrate. They were
allowed to acclimate for 10 min, and then interruptions of the photocell beams were
recorded for the next 10 min. Data were expressed as % depression where:

% depression =
(counts from nicotine-treated animals! counts from saline-treated animals) x 100.

Antagonists or saline were administered sc 10 min prior to saline or nicotine bitartrate.
Dose-response curves were determined for nicotine in the presence of 0, 0.3, 1 .0, and 3.0
mg/lcg of pempidine. For the structure-activity studies mecamylamine, pempidine and
mecamylamine analogs were administered sc 10 min prior to an ED84 dose of nicotine.
The data were expressed as % antagonism where:

% antagonism =
[ 1 -(% effect with antagonist pretreatment!% effect with nicotine alone)] X 100.
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The potency ratios for each compound compared to (±)exo-mecmaylamine were
determined where:
potency ratio =ADso of compound! ADso of (±)exo-mecamylamine.
Tail-flick reaction time to a heat stimulus was determined following drug or saline
administration using the method of D'Amour and Smith ( 1 94 1 ) as modified by Dewey et
al. ( 1 970). Pre-injection control values (2-4 sec) were determined for each animal. Mice
were retested 5 min after sc administration of nicotine bitartrate or saline and the latency to
the tail-flick response was recorded.

A 1O-sec maximum latency was set to prevent tissue

damage. Data were recorded as change in latency between pre- and post-injection testing
for each animal. Data were expressed as % maximum possible effect (% MPE) where:

% MPE =[(test latency - control latency)/(1O sec- control latency)] x 100.
Antagonists or saline was administered sc 10 min prior to saline or nicotine bitartrate.
Dose-response curves were determined for nicotine in the presence of 0, 0.03, 0. 1 , 0.3,
and 1 .0 mg/kg of pempidine. Mecamylamine analogs were evaluated for antagonistic
potency as described above.
Data Analysis
EDso and ADso values with 95% confidence limits (C.L.) and EDs4 values were
determined by the method of Litchfield and Wilcoxon ( 1 949). Dunnett's t-test was used to
make comparisons between the maximum effects produced by nicotine in the presence of
saline and each dose of antagonist (Dunnett, 1964).

llliJ.Ilts
Penmidine antal:onism
Nicotine produced a dose-responsive depression in spontaneous activity with an EDso
of 0.73 (0.49- 1 . 10) mg/kg as can be seen in Figure 2. Pempidine shifted the dose-response
curve for nicotine to the right in a dose-related manner. The EDso of nicotine was
increased to 1 .46 (0.95 - 2.25), 3.01 (2. 19 - 4.14), and 3.44 (2.06 - 5.74) mg/kg by 0.3,
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Figure 2. Antagonism of nicotine-induced depression of spontaneous activity by pempidine
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1 .0, and 3.0 mg/kg of pempidine, respectively. The increase in the ED50 of nicotine was
statistically significant from control at 1 .0 and 3.0 mg/kg of pempidine, as determined by a
lack of overlap in the 95% confidence intervals of the EDso's (figure 2). The maximum
effect of nicotine was not decreased significantly by pempidine. Pempidine alone had
slight effects on spontaneous activity at doses the doses studied in that 0. 1 , 0.3, 1 and 3
mg/kg produced 21 (14), 23 ( 1 2), 13 (7) and 22(22) % depression, respectively. A 1 0
mg/kg dose of pempidine alone produced 6 3 (4) % depression of spontaneous activity.
The pattern of shift for nicotine dose-response curves in producing antinociception by
pempidine was different than for depression of spontaneous activity, as can be seen in
figure 3. The dose-response curves for nicotine were shifted downward and to the right by
pempidine. The EDSO of nicotine was increased from 1 .94 (1 .22 - 3.07) mg/kg to 3.72
(2.03 - 6.8 1 ), 4.67 (2.67 - 8. 1 3), and 26.7 ( 1 5.25 - 46.54) mg/kg by 0.03, om , and0.30
mg/kg of pempidine, respectively. The increase in the ED so of nicotine was significant
with 0.3 mg/kg of pempidine, as can be seen from the lack of overlap in the 95%
confidence interval of the ED so compared to the saline-pretreated values.

The

dose-response curve for nicotine was shifted even farther to the right by 1 .0 mg/kg of
pempidine and the highest %MPE that could be obtained was 54% at 30 mg/kg of nicotine.
Maximum antinociception (100 % MPE) following saline pretreatment was produced by 3
mg/kg of nicotine. The maximum antinociception that was found in the presence of 0.3
and 1 .0 mg/kg of pempidine was produced by 30 mg/kg of nicotine and was 75 and 54

%MPE, respectively. The %MPE for these groups were found to be lower than the group
given 3 mg/kg of nicotine following saline-pretreatment at the 0.01 level of significance.
Doses of nicotine greater than 40 mg/kg with 0.3 and 1 .0 mg/kg of pempidine pretreatment
resulted in convulsions and death. Pempidine alone had no effect on tail flick latency at
doses up to

1 0 mg/kg.
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Structure-activity relationship
Nicotine produced depression of spontaneous activity and antinociception with ED84'S
of 1 .7 1 and 2.56 mg/kg, respectively. The (±)-exo-isomer of mecamylamine antagonized
the effect of nicotine at these EDs4 doses with ADso's of 0.24 (0. 1 4-0.42) mg/kg for
depression of spontaneous activity and 0.08 (0.02-0.29) mg/kg for antinociception. The
potency of pempidine was not found to be significantly different from that of
mecamylamine in that the ADso's for depression of spontaneous activity and
antinociception were 0. 10 (0.06-0.17) and 0. 1 3 (0.05-0.29) mg/kg, respectively. The
potency ratios for pempidine in antagonizing these effects can be seen in Table 1 . For
depression of spontaneous activity, (-)-exo-mecamylamine (IIA, Table 1 ) was
approximately equipotent with its racemic counterpart in that it has an ADso of
0.42(0.22-0.78) mg/kg. The (+)-isomer (liB) produced a maximum of 40% antagonism
of the hypoactivity at doses from 0.2 to 1 .0 mg/kg. No antagonism was found at 3.0
mg/kg of the (+)-isomer due to the fact that this dose produced 55% depression of
spontaneous activity when given 10 min prior to saline. Therefore, an ADso could not be
calculated for this compound in this assay. However, both the (-)- and (+)-antipodes of
exo-mecamylamine were found to have similar potency to their racemic counterpart for
antagonism of nicotine-induced antinociception in that their ADso's were found to be 0.09
(0.04-0.23) and 0.24 (0. 10-0.57) mg/kg, respectively.
The N-methylated derivative of (±)-exo-mecamylamine (III , table 1) was found to be
equipotent with the parent compound in that ADso's of 0.33 (0. 1 4-0.75) and 0. 1 7
(0. 1 1 -0.26) mg/kg were found for depression of spontaneous activity and antinociception,
respectively. None of these compounds other than (+)exo-mecamylamine were found
tohave agonist effects in either assay. The importance of the methyl groups in po sitions
adjacent to the nitrogen atom in mecamylamine is illustrated in table 1. The racemic
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Table 1 . Influence of isomerism and omission of methyl groups from mecamylamine.

COMPOUND

fr.

mecamylamine

±

endoJexo
exo

Rt

Ih

H

CH3 CH3 CH3 CH3

R3

&

lis

ReI. Potency a
Spont. Act. Antinocicep.

pempidine
IIA

1 .00

1 .00

0.40

1 .60

exo

H

CH3 CH3 CH3 CH3

1 .75

1.13

IIB

+

exo

H

CH3 CH3 CH3 CH3

_b

3.00

III

±

exo

CH3 CH3 CH3 CH3 CH3

1 .40

2. 1 3

lYE

±

exo

H

H

H

H

H

>40

> 1 25

IVD

±

endo

H

H

H

H

H

>40

> 1 25

VB

±

exo

CH3 H

H

H

H

>40

> 1 25

VD

±

endo

CH3 H

H

H

H

>40

> 1 25

VI

±

exo

CH3 H

H

CH3 H

4.92

3 1 .25

a Relative potency compared to mecamylamine as described in text.
b ADso could not be detennined for reasons given in Results.
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isomers of exo- and endo-2-norbomamine (NE and IYD, respectively) were found to be
inactive up to 10 mg/kg in both assays. The maximum antagonism produced for
depression of spontaneous activity was 1 0% for the exo-isomer at 1 0 mg/kg.

No

antagonism was seen with the endo-isomer up to the same dose. For antinociception, the
maximum antagonism that could be produced at 10 mg/kg was 25 and 1 8% for the exo
and endo-isomers, respectively. The N-methylated counterparts of these compounds (VE
and YD, table 1 ) were found to be equally inactive. The maximum antagonism of
nicotine-induced depression of spontaneous activity by the N-methylated derivatives of
exo- and endo-2-norbomamine was found to be 37 and 1 7 % , respectively.

For

antinociception, these values were 32 and 66% at 10 mg/kg of the exo- and endo-isomers,
respectively. None of these compounds had agonistic effects in either assay at 10 mg/kg.
The addition of one methyl group to the 3-position of VE was found to restore efficacy in
that compound VI antagonized nicotine-induced hypoactivity and antinociception with
AD50's of 1 . 1 8 (0.74- 1 .89) and 2.50 ( 1 .22-4.86) mg/kg, respectively (table 1).
The effect of translocating the methyl groups adjacent to the nitrogen to various
positions on the norbomane ring is demonstrated in table 2. The 2-desmethyl derivative of
(±)-endo-mecamylamine (compound VII, Table 2) possesses similar potency to
(±)-exo-mecamylamine, with ADso's of 0.20 (0. 1 3-0.3 1 ) and 0. 1 3 (0.07-0.27) mg/kg for
antagonism of nicotine-induced depression of spontaneous activity and antinociception,
respectively. Translocation of the 2-methyl group to the I -position has little effect on the
activity of mecamylamine, as can be seen with compounds VIllA and VIIIB. The (-)- and
(+)-exo-isomers were found to have AD50's of 0.29 (0. 1 2-0.44) and 0.25 (0. 1 5 -0.42)
mg/kg for depression of spontaneous activity, respectively.

For antagonism of

nicotine-induced antinociception, the (-)- and (+)-exo-isomers were found to have
respective ADso's of 0.89 (0.43- 1 . 84) and 0.22 (0.09-0.56) mg/kg. Their (-)- (IXA) and
(+)-endo (IXB) counterparts had similar potency in that their respective ADso's for
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Table 2. Influence of transposition of methyl groups of mecamylamine.

COMPOUND
vn

±L:.

endo/exo

&1

&2

&3

±

endo

H

H

CH3 H

0.80

1 . 60

exo

CH3 H

CH3 H

1 .08

1 1 . 10

exo

CH3 H

CH3 H

1 .04

2.75

endo

CH3 H

CH3 H

0.83

1 .50

VllIA
VllIB

ReI. Potency a
Spont. Act. Antinocicep.

+

IXA

&

IXB

+

endo

CH3 H

CH3 H

1 .08

2.38

X

±

exo

CH3 H

H

CH3

4.50

1 2.63

XM

±

exo

CH3 CH3 H

CH3

8.88

1 2. 1 3

a Relative potency compared to mecamylamine as described in text.
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depression of spontaneous activity are 0.20 (0. 1 4-0.30) and 0.26 (0.20-0.34) mg/kg.
They had similar potency in antagonizing nicotine's antinociceptive effects in that the
A D so's of the (-)- and (+)-isomers were found to be 0. 1 2 (0.002-9.66) and 0. 1 9
(0.02- 1 .60) mg/kg, respectively. Translocation of the 3-gem-dimethyl groups to the
7-position (compound X, table 2) was found to reduce the potency of mecamylamine in
that the ADso's for depression of spontaneous activity and antinociception were 1 .08
(0.50-2.29) and 1 .01 (0.58- 1 .76) mg/kg, respectively. The N-methylated counterpart
(XM, table 2) was found to have similar potency in that respective ADso's of 2. 1 3
( 1 . 1 0-4. 1 1 ) and 0.97 (0.76- 1 .24) mg/kg were found for depression of spontaneous
activity and antinociception. No evidence of agonistic activity was found for any of these
compounds at the highest dose tested for antagonism.
The effect of adding a pyridinyl group to the nitrogen atom of mecamylamine can be
seen in the series of compounds in table 3. These compounds were not found to possess
full activity up to 10 mg/kg, and therefore the maximum % antagonism found is reported
since ADso values could not be calculated. None of these compounds were found to
possess agonistic activity in either assay up to 10 mg/kg. Addition of a pyridinyl group to
the N-methyl of compound VA (table 1 ) does not increase the activity (XI, table 3) in that
the antagonism produced by 10 mg/kg of this compound was not significantly greater than
VA. Furthermore, the antagonism was not dose-responsive at lower doses. Addition of an
N-methyl (compound XII) to XI or alteration of the methylene group connecting the
nitrogen to the pyridine ring (compounds XIII and XIV) did not affect the activity as well.
The antagonism seen with these compounds was variable and not statistically significant.
Addition of methyl groups to the positions adjacent to the nitrogen was not found to result
in an increase in antagonism. Addition of a pyridinyl group to the nitrogen of VIIIA (table
2) through a methylene group (XVA) abolishes the activity of this compound in that no
significant antagonism was seen in either assay. The (+)-isomer (XVB) as well as the
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Table 3. N-pyridinyl-substituted derivatives of mecamylamine

Max. Antag. a

COMPOUND

±/.;.

!<ngQ[\<xQ

RI

R2

&

�

S1K2nI. A\;I. AnIiIl�i�12.

XI

±

exo

H

H

CH2

H

6

47

XII

±

exo

H

CH3

CH2

H

9

40

XIII

±

exo

H

H

XI

H

0

17

XIV

±

exo

H

H

X2

H

21

48

exo

CH3 H

CH2

CH3

12

28

exo

CH3 H

CH2

CH3

30

14

endo

CH3 H .

CH2

CH3

0

10

endo

CH3 H

CH2

CH3

15

29

exo

CH3 CH3

CH2

CH3

28

0

exo

CH3 CH3

CH2

CH3

44

27

XVA
XVB

+

XVIA
XVIB

+

XVIIA
XVllB

+

a Maximum percent antagonism found at doses up to 10 mg/kg.
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respective (-)- and (+)-endo isomers (XVIA and XVIB, respectively) were found to be
inactive up to 10 mg/kg. Addition of an N-methyl group to the (-)- and (+)-exo-isomers
(XVlIA and XVIIB , respectively) had no effect on their activity.
4. Discussion
It has been inferred that ganglionic blockers that penetrate the blood-brain barrier
antagonize nicotine centrally in a purely noncompetitive fashion based upon the fact that
they do not displace 3 H-nicotine binding
However, the correlation between the

in vitro

in vivo

from brain tissue (Martin, 1 9 86).

pharmacology of compounds and their

ability to displace radiolabelled ligands from tissue determines the relevance of binding
data. It is therefore necessary to evaluate the effects of these compounds in the intact
animal with regard to their competitive or noncompetitive nature. Pempidine shifts the
dose-response curves for nicotine in producing depression of spontaneous activity in a
manner consistent with competitive antagonism, since the EDso's of nicotine are increased
by doses of pempidine that do not alter its maximum effect These data are consistent with
the findings of Stolerman et al. (1982), in that mecamylamine's antagonism of nicotine in
decreasing rate of responding in a drug-<iiscrimination paradigm was completely overcome
by increasing the dose of nicotine. Questions have arisen as to whether the effects of
nicotine on spontaneous activity are receptor mediated. Stolerman et al. ( 1982) suggested
that depressant effects are a nonspecific measure of nicotine's central activity. On the other
hand, the ability of central, but not peripheral, antagonists to block this effect coupled with
the fact that tolerance develops to the depressant effects of nicotine suggests that specific
central receptor mechanisms are involved in nicotine's alteration of spontaneous activity.
However it is possible that nicotine's ability to overcome pempidine's antagonism of
depression of spontaneous activity may be due to non-receptor mechanisms that are not
blocked by pempidine.
The pattern of shift of nicotine dose-response curves by pempidine for the production of
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antinociception is different from what was found for depression of spontaneous activity
and is strikingly similar to that reported by van Rossum et al. ( 1962) in the guinea pig
jejunum. This type of antagonism was termed by van Rossum as "dualistic" antagonism,
in that both the characteristics of competitive and noncompetitive antagonism are displayed.
It is not clear from van Rossum's data if there is a dose of pempidine that alters the EDso of
nicotine while failing to alter its maximum effect, as statistics were not reported for these
measures. In this study, it is clear that at doses of pempidine where the EDso of nicotine is
significantly increased, the maximum effect that can be obtained with nicotine is decreased.
This suggests that pempidine acts noncompetitively to antagonize nicotine-induced
antinociception in the mouse. The mouse tail-flick assay has an advantage in that the range
of doses of nicotine that can be studied is not as limited as it is for some behavioral tests.
The maximum dose of nicotine that can be used in drug-discrimination studies with nicotine
is limited due to rate-suppressive effects at higher doses that

are

not antagonized by

mecamylamine. This is not a trivial point when one is atttempting to determine if the
antagonism can be completely reversed by increasing the dose of the agonist. However, in
vivo

assays possess limitations in predicting the mechanism of action of compounds.

Obviously, many events occur following the administration of a compound other than
receptor activation or blockade. The researcher has less control over the metabolism and
distribution of compounds

in vivo

than

in vitro.

Nicotine produces changes in many

neurotransmitter systems and changes in behavior following nicotine administration
undoubtedly occur as a result of effects on more than one system. An example of one such
limitation in this study is the range of pempidine doses that could be tested in the
spontaneous activity assay. The range of doses of pempidine was limited due to its
depressant effects. This may account for the inability to find a decrease in the maximum
depression produced by nicotine following pempidine pretreatment
The difference in the nature of pempidine's antagonism of these effects may also be due
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to multiple mechanisms of either nicotine or pempidine. Pempidine may compete for a
select subset of nicotine binding sites that are responsible for nicotine's depressant effects
and that have not been elucidated under the conditions that have been studied for agonist
binding in vitro to brain tissue. Another explanation that may attribute for the discrepancy
between pempidine's ability to antagonize nicotine's depressant and antinociceptive effects
is noncompetitive antagonism of spare receptors.

This theory, first proposed by

Stephenson ( 1 956), assumes that the maximum possible effect that can be achieved with a
compound depends upon both the number of available receptors and the physiological
limits of the responding tissue. A spare receptor pool exists when the tissue responds
maximally while only a fraction of the total receptor pool is occupied. A decrease in the
maximum response is seen only when the receptor pool is depleted to a crltical level by a
noncompetitive antagonist. This theory has been supported by the studies of Furschgon
(1955) and Nickerson ( 1 956). The pattern of the shift of the nicotine dose-response curves
in producing depression of activity by pempidine is consistent with this model. The lack of
pempidine's ability to decrease the maximum possible effect of nicotine-induced
hypoactivity may indicate that the spare receptor pool for this effect is not sufficiently
depleted by doses of pempidine up to 3 mg/kg. Studying the binding of the agonists as
well as antagonists under in situ or in vivo conditions may provide insights as to which of
these explanations best accounts for the antagonism of nicotine-induced depression of
spontaneous activity and antinociception by pempidine.
The structural alterations made in the mecamylamine molecule reveal the positions
within the molecule that are important for its antagonistic activity. TIle compounds in table
1 clearly demonstrate that the methyl groups in the N and 3 positions

are

crucial for

activity. It is further illustrated in table 2 that at least 3 methyl groups must be present at the
N, 1 , 2 and 3 positions for optimal potency. Furthermore compounds X and XM in table 2
demonstrate that the presence of methyl groups in the 7- as opposed to the 3-position
significantly reduces the potency, possibly due to increased sterlc hindrance of the
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nitrogen. Table

3 clearly shows that addition of bulky substituents to the

the activity of these compounds.

nitrogen reduces

One finding that was consistent with all compounds

tested was the lack of effect of stereoisomerism on their activity and potency. This can be
seen by comparing all compounds that differ in designation by A or B, with A consistently
denoting the (-)-isomer and B denoting its (+)antipode.

The data show that exo/endo

isomerism is without effect on the activity and potency of these compounds as well.
findings are in agreement with those of S tone et aI.
nicotine-induced convulsions and pupil dilitation in
the N,

mice.

( 1 956)

These

for antagonism of

These investigators found that of

2 and 3 methyls and the methylene bridge, at least three must be present for optimal

activity and potency. Furthermore, increasing the bulk of the N-substitution decreased the
potency of the antagonists in these assays. They likewise found that stereoisomerism had
little effect on the potency of all analogs tested. Therefore, the activity and potency of
mecamylamine seems to depend only upon the presence and position of the methyl groups
adjacent to the nitrogen atom in both the CNS and at the ganglia
The methyl groups may serve two possible roles in the activity and potency of
mecamylamine.

They may serve to provide steric bulk to block a binding site or ion

channel, or as electron-donating groups that increase the base strength of the nitrogen.
Bretherick et aI.

( 1962)

examined the structure-activity relationships of a number of

pempidine analogs for antagonism of nicotine-induced contractions of guinea-pig ileum.
They found that attachment of electron-donating groups to the nitrogen atom in pempidine
increased potency, whereas electron-withdrawing groups in this position decreased
potency. Therefore the base strength of the nitrogen atom in these compounds appears to
be important for their potency.
Such meager structural requirements for the activity of mecamylamine suggests that, if
a binding site exists for these compounds, it is not likely to be the agonist binding site. The
nitrogen of mecamylamine is not contained within a ring, which was found to be necessary
for agonistic activity (Chance et aI. ,

1978).

Furthermore, the pyrrolidyl nitrogen of
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nicotine is in close proximity to the pyridine ring, and increasing the distance between the
two has been shown to decrease the activity of nicotinic agonists (Chance et aI., 1 97 8).
Addition of such a moiety to active structural isomers of mecamylamine was found to
abolish activity suggesting that the nitrogen cannot gain access to its site of action with such
bulky substituents in place. These [mdings lend support for noncompetitive antagonism of
nicotine by these compounds, as it does not appear that the agonists and antagonists
possess similar structural requirements for their activity.

III.

Receptor Binding Interactions of Nicotinic Agonists and Antagonists

Introduction
The existence of "receptive substances" for the action of nicotine was ftrst proposed by
Langley ( 1 905) as a result of observations regarding nicotine's ability to contract skeletal
muscle. Since that time, nicotinic receptors have been postulated at the autonomic ganglia

and in the brain as well Originally, evidence for the existence of central nicotinic receptors
was that nicotine produced a myriad of behavioral effects that were selectively antagonized
by ganglionic-blocking agents that penetrated the blood-brain barrier. S ince the early
1 970's numerous attempts have been made to characterize a nicotinic binding site to brain
tissue. A variety of cholinergic agonists and antagonists, as well as a-neurotoxins and
nicotine itself have been used. This subject has been reviewed in detail by Martin ( 1986).
The relevance of the nicotine binding sites that have been characterized in brain remain
in question with regard to nicotine's pharmacology. One of the most consistent ftndings is
that none of the central nicotinic antagonists, such as mecamylamine and pempidine,
displace 3H-nicotine binding to brain. Although this suggests that these compounds act as
noncompetitive antagonists, pharmacological studies that address this issue have led to
ambiguous ftndings. Mecamylamine has been shown to possess both competitive and
noncompetitive characteristics in its antagonism of nicotine at the ganglia (van Rossum et
al. , 1 962) and

in the eNS (Stolerman et al. , 1 987). It has also been shown that the nicotinic

receptor can exist

in a variety of states.

�ome of these states are termed

"desensitized"

states due to the fact that agonist binding does not lead to receptor activation.

Many

investigators have postulated that the nicotine binding sites characterized to date in vitro
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are
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in fact desensitized receptors. 3 H-Nicotine binding

in situ

to brain slices has been

characterized by a number of investigators (Marks et al., 1986; Clarke et ai. , 1 984).
However, the sensitivity of these binding sites to displacement by the central nicotinic
antagonists has not been documented. Binding studies with radiolabelled reversible
ganglionic blockers such as mecamylamine and pempidine in vitro and in situ have not been
documented as well.
Over the last decade, quantitative receptor autoradiography has proven to be a valuable
tool for the determination of radioligand binding to discrete brain areas. It has been applied
to the study of many receptor-ligand interactions, including nicotine. An excellent review
on the methods, advantages and possible pitfalls of this technique has been provided by
Kuhar ( 1985).

Other pertinent methodological considerations regarding tritium

quantitation by the use of tritium-sensitive films has been provided by Geary et al. ( 1985)
and Geary and Wooten (1985). Quantitative autoradiography allows the investigator to
study radioligand localization patterns
advantages over classical

in vitro

in situ

using tissue slices. This method offers

methods in that the architecture of the tissue remains

intact and quantitation is more sensitive in that discrete brain areas may be studied. The
advent of computerized densitometry has rendered the technique even more amenable to
standardization and quantitation (Goochee et ai., 1980). Nicotinic receptors have been
studied autoradiographically using these techniques by a number of investigators (Clarke et
al., 1985a; Segal et al., 1978; Duggan et al 1976). The pattern of localization in brain
.•

that has been found for 3H-nicotine is consistent for all of these studies. Furthermore, the
localization pattern of 3H-nicotine binding sites is identical to that of 3H-acetylcholine in the
presence of a muscarinic antagonist (Clarke et al., 1985a). The effect of the antagonists on
3 H-nicotine binding

in situ

to any of these brain areas remains to be documented

autoradiographically.
Therefore

in situ

studies were carried out to determine the sensitivity of 3H-nicotine

binding to displacement by nicotinic antagonists using rat brain. The characteristics of
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3H-nicotine binding were compared in situ and in vitro. The in situ 3H-nicotine binding in
the presence and absence of nicotinic antagonists was further quantitated
autoradiographically in discrete brain areas. The binding characteristics of 3H-pempidine
were determined in vitro and in situ

to rat brain for comparison with

those of the agonists

and to test the hypothesis that the agonists and antagonists may share binding sites that
have not been elucidated to date.
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Materials and Methods

�
Male ICR mice (Dominion Laboratories, Dublin, VA) weighing 1 8-25 g were used for
the

in vitro

binding experiments. Male Sprague-Dawley rats (Dominion Laboratories,

Dublin, VA) weighing 200-250 g were used for
experiments. All animals were kept on

a

in situ

binding and autoradiography

12 hr light/dark cycle and given Purina Rodent

Chow (Purina Inc., St. Louis, MO) and water ad libitum.

Materials
[3 H]-L-Nicotine (80 Ci/mrnol) was purchased from New England Nuclear (Boston,

MA), and purity was determined by thin-layer chromatography (methanol:chloroform:
ammonium hydroxide, 70:30:0.2).

pH]-Pempidine (80 Ci/mmol) was a gift from Dr.

Richard Young, New England Nuclear (Boston, MA), and purity was determined by
thin-layer chromatography as described for [3 H]-L-nicotine and by HPLC using a
Flo-one\Beta radioactive flow detector (Radiomatic Instr. and Chern. Co., Inc., Tampa,

FL). (-)-Nicotine and (+)-nicotine were kindly donated by Dr. Everette L. May of Virginia
Commonwealth University (Richmond, VA) as their bitartrate salts. (-)-Cotinine was a gift
from Dr. Edward Bowman of Virginia Commonwealth University. (±)-Atropine sulfate,
bethanechol hydrochloride, hexamethonium, (±)-anabasine, (-)-cytisine, mecamylamine
and pempidine were purchased from Sigma Chemical Co. (St. Louis, MO).

PH1-L-Nicotine bindin� in vitro
PH]-L-Nicotine binding was performed

in vitro

according to the method of Scimeca

and Martin ( 1 988) with minor modifications. Tissue homogenate was prepared from
whole mouse brain (minus cerebellum) in 1 0 volumes of ice-cold 0.05 M Na-K phosphate
buffer (pH 7 .4) and centrifuged ( 1 7500 g, 4 0c) for 30 min.

The pellet was then
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resuspended in 20 volumes of ice-cold glass-distilled water and allowed to remain on ice
for 60 min before being centrifuged as before. The resulting pellet was then resuspended
to a final tissue concentration of 40 mg/ml of buffer. To various concentrations of
[3H]-L-nicotine was added 0.5 ml of tissue homogenate for a fmal incubation volume of 1
ml.

Specific binding was defined as the difference in the amount of binding in the presence

and absence of 100 IJ.M L-nicotine tartrate and determinations were made in triplicate. The
tissue was incubated for 2 hr at 4 °C and then rapidly fIltered through Whatman GF/C filter
discs (previously soaked overnight in 0. 1 % poly-I-lysine) using a vacuum manifold
(Millipore Corp., Bedford, MA). Following three consecutive washes with ice-cold
buffer, the fIlter discs were allowed to air dry and then placed in scintillation vials with 1 0
ml

of Budget-Solve (Research Products International Corp., Mt. Prospect, IL). The vials

were vigorously shaken for 1 hr and then

counted by scintillation spectrometry.

Correction for quench was by external standardization. Following transformation of the
data by the method of Scatchard (1949) the K.! and Bmax values were determined using the
LIGAND program of Munson and Rodbard (1980) supplied by NllI.
Displacement of pH]-L-nicotine binding at 1 nM was determined in the presence of
increasing concentrations of various ligands and converted to % displacement where:

% displacement

=

binding displaced by ligand concentration + binding

displaced by 100 IJ.M nicotine tartrate.

The ICso's were determined from a plot of the log concentration vs. %displacement and
converted to � values by the method of Cheng and Prusoff (1973).

PHl-L-Nicotine bindin!: in situ
Rats were decapitated and their brains quickly removed and frozen in isopentane at -60
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°C. The brains were then mounted onto cryostat chucks and stored at -70 °C until
sectioned. Following equilibration of the mounted brain at -20 °C for 1 hr, 20 � sections
were taken and thaw-mounted onto slides coated with 0.5 % gelatin (w/v) and 0.05%
chromium potassium sulfate (w/v). The sections were stored overnight under vacuum in a
dessicator at 4 °C and used for binding studies the following day. Sections containing
primarily frontal cortex and caudate putamen (A8900-A6300, Konig and Klippell, 1 963)
were used for the binding isotherms and Scatchard analysis, as these sections have no
longitudinal gradient of binding for [3HJ-L-nicotine (Clarke and Pert, 1985). The slides
were placed in slide mailers (Thomas Scientific, Swedesboro, NJ) and incubated as
described for the in vitro assay. Following incubation, the slides were removed, placed in
staining racks and carried through four consecutive 500 ml washes of ice-cold buffer. The
sections were then removed by wiping the slides twice with Whatman GF/C filters. The
duplicate fIlters were then placed in the same scintillation vial, solubilized overnight with 1
ml

of TS-2 (Research Products International Corp., Mt. Prospect, IL). The samples were

then acidified with 1 ml of I N HCI and counted by scintillation spectroscopy in 1 0 ml of
Budget-Solve (Research Products International Corp., Mt. Prospect, IL). Correction for
quench was by external standardization. The data were analyzed as described above. The
amount of protein per section was determined by the method of Bradford ( 1976) by
collecting 5 adjacent sections and homogenizing in 1 ml of buffer.
Displacement studies were performed as described for the in vitro assay using 2 nM of
[3 H]-L-nicotine. The data were analyzed in the same manner as well.

PHl-kNjcotine Autoradiomwhy
Autoradiograms of the [3HJ-L-nicotine binding to various sections were obtained by
using conditions identical to the

in situ

assay and a 1 0 nM radioligand concentration.

Nonspecific binding was assessed in the presence of 1 00 �M nicotine tartrate.
Displacement of this binding was also assessed in all areas in the presence of 1 00 �M
pempidine tartrate. Instead of wiping the sections from the slides following the washes,
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the

slides were rapidly dried under a stream of cool, dry air and placed in a dessicator under

vacuum at 4 °C overnight to assure unifonn hydration. The sections were then apposed in
duplicate to tritium-sensitive film (Hyperfilm_3H, Amersham Corp., Arlington Hts., IL)
along with a range of tritium standards (0. 1 14-9.468 nCi/mg) rH-microscales, Amersham
Corp., Arlington Hts., IL) for 10 weeks. All studies were conducted in triplicate. Section
designations were made according to the nomenclature of Konig and Klippel ( 1 963), where
the number of microns rostral to an FO plane is given, so that larger numbers represent
more rostral sections. The FO plane is defined as the plane dividing the diencephalon and
the mesencephalon.

The autoradiograms were quantitated using a computerized

densitometric system (MCID System, Imaging Research Inc., Toronto, Canada) and an
mM PC. The % displacement was calculated as described above.
Calibration of 3H-microscales aeainst brain paste standards
The 3H-microscales were calibrated against brain paste standards to correct for tritium
quench. Brain paste was obtained by homogenizing 3 rat brains in 1
water. The paste was then centrifuged for 30 min to remove

air

mI

of deionized

bubbles. Aliquots were

weighed into microfuge tubes and 50 J.Ll of various concentrations of PHl-L-nicotine were
added for final standard values of nCi/mg tissue, wet weight. The paste standards were
then vonexed for 5 min and centrifuged for 1 0 min to remove any

air

bubbles. Actual

standard values were then obtained by weighing aliquots of the radioactive brain paste
standards on Whatman GF/C filters, which were then solubilized and counted as described
for the tissue sections. The standards were then immersed in liquid nitrogen, mounted onto
cryostat chucks. Triplicate 20 �m sections were taken of each brain paste standard,
thaw-mounted onto gelatin-coated slides and stored as described for the autoradiographic
sections. The brain paste standards and 3H-microscales were then apposed to the
tritium-sensitive film for 10 weeks. Values for the 3H-microscales were obtained by fitting
a third degree polynomial equation to the brain paste standards and these calibrated values
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were used for quantitation of the radioactivity in each brain area.
pm-Pempidine bindin� in vitro and in siw
[ 3 H]-Pempidine binding to mouse brain was assessed

in vitro

using the assay

conditions described for PHl-nicotine. This binding was further assessed with alterations
of time, temperature, buffer and protein concentration. Displacement of 1 nM of
[3 H]-pempidine by various concentrations of nicotine and pempidine was assessed as
described for [3Hl-nicotine in vitro. PHl-Pempidine binding to rat brain was assessed in
siw

as described for PHl-nicotine. The time course of PHl-pempidine binding was also

assesed

in siw

at 4, 25 and 37 °e. Using assay conditions for pH] -nicotine binding,

pH]-pempidine binding was assessed to sections from A IO,OOO to A 1 200 (Konig and
Klipell, 1963). PHl-pempidine binding was assesed in situ as described for PHl-nicotine
binding using two alternate buffers of 10 mM HEPES or 50 mM Tris. Displacement of 1
nM of pH]-pempidine by various concentrations of nicotine and pempidine was assessed
as described for [3Hl-nicotine in siw.

Pm-kNicotine bindin� in vitro and in siw
PH]-L-Nicotine was found to label two binding sites in mouse brain in vitro . As can

be seen in figure 4, PHl-L-nicotine bound to brain homogenate in vitro in a concentration
dependent manner and displayed the characteristics of two binding sites, as can be seen by
the

Scatchard transformation of the isotherm. The specific binding ranged from 45 to 85%

of the total binding. The binding appears to approach saturation at 10 nM, however the
binding increases linearly at concentrations higher than 20 nM. Resolution of the Scatchard
plot yields K.J and Bmax values of 0.9 nM and 12 fmoVmg protein, respectively for the high
affmity site. The low affinity site was found to have a K.! of 194 nM and Bmax of 1 265
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Figure 4. 3 H-L-Nicotine binding to mouse brain homogenate in vitro
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fmoVmg protein.
PH1-L-Nicotine binding was found to display similar characteristics in situ

to

rat brain

slices as can be seen in figure 5. The binding was saturable and the specific binding was
found to be 65 to 90% of the total. Transformation of the isotherm gave yield to a
curvilinear Scatchard plot as with the in vitro binding. Resolution of the Scatchard plot
resulted in K.J and Bmax values of 2 nM and 67 fmoVmg protein, respectively, for the high
affmity site. These values for the low affinity counterpart were found to be 99 nM and 482
fmoVmg protein, respectively. The

in situ

binding of pHl-L-nicotine was selective to

displacement by nicotinic agonists, as can be seen in figure 6. Displacement of this binding
by the nicotinic agonists (-)-cytisine, (-)-nicotine, (+)-nicotine and (±)-anabasine gave Ki
values of 0.5, 2.5, 42 and 94 nM, respectively. Displacement with the muscarinic
compounds (±)-atropine and bethanechol resulted in Ki values of 14 and 6.4 �M,
respectively. The � for hexamethonium was 76 �M, whereas (-)-cotinine, pempidine and
mecamylamine did not compete for this binding effectively as their � values were greater
than 1 000 �M.

Autoradio�phy of PHl-knicotine bjndin�
Quantitation of autoradiograms of in situ [3Hl-L-nicotine binding to various sections
resulted in the data presented in tables 4, 5 and 6. The data presented in table 4
demonstrates the localization pattern of nicotinic receptors in sections A l 0,000 to A6200,
consisting primarily of frontal cortex and caudate putamen (figure 7). The largest number
of nicotinic receptors were found in the septal nucleus (sl), cortex (COR) and caudate
putamen (cp ) and the specific binding ranged from 65 to 82% of the total for these regions.
Although some displaceable binding was found in the fornix (F), it represented only 43%
of the total. The specific bindin g found in the corpus callosum (TCC and RCC), anterior
commisure (CA), globus pallidus (GP) and triangular septal nucleus (ts) was less than 14%
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Figure 7. Anatomical map of section A7roJ (Konig and KlippeU, 1963)

Table 4. Distribution of 3H-L-Nicotine binding and displacement by perilpidine to sections
A 1O,roJ - A6200

Brain area

�

Displaced a
Pempidine

% Displacement b

COR

5.344 (2. 1 39)

3 . 1 65 ( 1 .244)

59

cp
sl
F

4.27 1 ( 1 .670)

2.62 1 (0.800)

61

7.809 (3.299)

6.046 (3.000)

77

2.956 ( 1 . 1 14)

1 . 3 1 5 (0.783)

44

TCC

0.534 (0. 3 1 0)

0.366 (0.354)

69

RCC

0.7 1 3 (0.358)

0.053 (0.053)

7

CA

1 .473 (0.385)

0.998 (0.5 1 3)

68

OP

0.619 (0.536)

0.384 (0.259)

62

15

0.909 (0.909)

0.8 1 9 (0. 8 1 9)

90

a Mean (s.e.m.) fmoVmg wet weight tissue
b % displacement with l00 !J.M of pempidine as defined in text
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of the total binding. Pempidine was found to compete for the pH]-L-nicotine binding most
effectively in the septal nucleus, cortex and caudate putamen, with 77, 59 and 61 %
displacement, respectively. There was little displacement by pempidine in the other areas
of these brain sections. An anatomical map of these areas is shown in figure 7.
The localization pattern of nicotinic receptors in sections A5700 to A4000, which are at
the level of the thalamus and hippocampus is shown in table 5. The largest number of
nicotinic receptors were found in the medial habenula (mh), dorsolateral geniculate bodies
(dcgl) and lateroventral and ventrodorsal thalamic nuclei (tl and tvd), followed by the
ventrolateral thalamic nuclei (tv) and the cortex (COR). Little specific binding was found in
the hippocampus (HI) and hippocampal funiculus (FH). Displacement of this binding by
100 JlM of pempidine was greatest in the medial habenula, dcgl, thalamic nuclei and
cortex, and least in the hippocampus and hippocampal funiculus. An anatomical map of
these regions is demonstrated in figure 8 and representative autoradiograms

are

shown in

figure 9.

Table 5. Distribution of 3H-L-Nicotine binding and displacement by pempidine to sections
A5700 - A4000
Displaced a
Pempidine

Brain area

�

COR

1 1 .369 (4.288)

% Dis.placementb

9.68 1 (5.536)

85
93

HI

6.448 (3.925)

6.009 (4.346)

FH

0.285 (0. 146)

0. 173 (0. 1 58)

61

mh

56.854 ( 1 0. 1 36)

4 1 .325 ( 1 9. 566)

73

dcgl

3 1 .559 (5.41 6)

23.066 ( 1 2.268)

73

tl

22.573 (3. 1 29)

1 1 .95 1 (8. 1 68)

53

tvd

1 6.259 (2.624)

8 .9 1 6 (5.760)

55

tv

1 0.469 ( 1 .4 1 0)

5. 1 36 (2.7 6 1 )

49

a Mean (s.e.m.) fmoVmg wet weight tissue
b % displacement with 100 J.1M of pempidine as defined in text

60

HI
---�-&
dcg l --�-

mh

FH

tl
tvd

Figure 8. Anatomical map of section A4400 (Konig and KlippeU, 1963)

Figure 9. Representative autoradiograms of 3H-L-nicotine binding to section A4400
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The localization pattern of nicotinic receptors in sections A2400 to A 1 200 is
demonstrated in table 6. The greatest amount of rH]-L-nicotine binding was found in the
interpeduncular nucleus (IPN), superficial gray layer of the superior colliculus (SGS),
medial geniculate bodies (mcgm), substantia nigra pars reticulata (SNR) and cortex (COR).
The specific binding in these regions represented 66 to 96% of the total binding. Less
binding was found in the hippocampus (HI), reticular formation (FOR) and the dorsal
commissure of the hippocampus (CFD) and the displaceable binding was only 52, 47 and
32% of the total for these areas, respectively.

The greatest degree of pempidine

displacement oPH-L-nicotine binding was in the interpeduncular nucleus, superficial gray
of the superior colliculus, medial geniculate bodies, substantia nigra pars reticulata and
cortex. Pempidine did not displace a significant amount of binding in the hippocampus and
dorsal hippocampal commissure. An anatomical map of these regions is demonstrated in
figure 10 and representative autoradiograms are shown in figure 1 1.

Table 6. Distribution of 3H-L-Nicotine binding and displacement by pempidine to sections
A2400 AI200
-

Brain area

Displaced a
�
Pempidine

% Displacementb

COR

5.838 (2. 190)

3.594 ( 1 . 1 84)

62

HI

2.946 ( 1 .928)

2.23 1 ( 1 .4 1 6)

76

CFD

0.973 (0.396)

1 . 050 (0.620)

108

SGS

20.053 (4.878)

1 2.273 (7.689)

62

mcgm

1 1 .254 (4. 196)

8.509 (3.828)

76

SNR

6. 325 (2.744)

4.500 ( 1 . 874)

71

2. 1 5 6 ( 1 . 806)

1 .628 ( 1 . 386)

76

75.865 ( 1 2.2 14) 47 . 1 1 6 (25.878)
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FOR
IPN

a Mean (s.e.m.) fmoVmg wet weight tissue
b % displacement with 100 jlM of pempidine as defined in text

62
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Figure 1 0. Anatomical map of section A 1 800 (Konig and Klippell. 1 963)

Figure 1 1 . Representative autoradiograms of 3H-L-nicotine binding to section A 1 800
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The displacement of [3H]-L-nicotine binding was also assessed in the presence of a
range of nicotine and pempidine concentrations in those areas containing the largest number
of nicotinic receptors. The % displacement of 3H-L-nicotine binding to various areas in
section A7000 by 1, 10, and 100 jlM of nicotine and pempidine can be seen in figure 12.
Nicotine competed effectively for this binding at all concentrations and displaced 78 ± 6, 77
± 6, and 49 ± 10 % of the total binding in the cortex, caudate putamen, and septal nucleus,
respectively, at a concentration of 100 jlM. The respective values for pempidine at this
concentration were 1 2 .2 ± 4.3, 8.2 ± 3. 1 , and 4 ± 4.

At 1 jlM, the amount of

3H-L-nicotine binding displaced by pempidine was 7 ± 4, 8 ± 6, and 1 ± 1 % of the total in
the cortex, caudate putamen, and septal nucleus, respectively. These values for 1 jlM of
nicotine were not different from those found with 100 jlM.
A similar pattern is seen with the other two remaining sections, as can be seen with
section A4400 in figure 1 3 and with section A 1 800 in figure 14. Nicotine competed for
3H-L-nicotine binding effectively in the cortex, various thalamic nuclei, and medial
habenula, as can be seen in figure 13. Pempidine displaced only 7 ± 3, 8 ± 5, 4 ± 2, 14 ±
4 and 6 ± 1 % of the total 3H-L-nicotine binding in the cortex, lateroventral thalamic
nucleus, ventrodorsaJ thalamic nucleus, ventrolateral thalamic nucleus and medial habenula,
respectively, at a concentration of 100 jlM. Figure 14 also demonstrates the inability of
pempidine to compete effectively for 3H-L-nicotine binding to the cortex, hippocampus,
superior colliculus, medial geniculate body, interpeduncular nucleus and reticular formation
at this relatively high concentration. As with the two preceding sections, nicotine was
found to compete effectively for this binding at all concentrations studied.

64

Cortex
1 00
'E
•

E

80

•
u
•

60

•

40

�

20

Q.
is

0

�
i

.

----'

0

2

3

Septal nucleus
1 00
'E
•

E

80

•
u
•

60

•

40

Q.
Q
�

20
0

r--f-1
0

2

3

Caudate putamen
1 00
'E
•

E

80

•
u
•

60

•

40

�

20

Q.
is

0

Figure

12.

�
i
0

,

1
Log Cone ()l.M)

..
2

3

3
Displacement of H-L"nicotine binding to regions in section A7000 by nicotine

and pempidine

( . ).

( D)

6S

Cortex

1 00
C

�•

II
•

Ii.
·
Ci
'#

80
80

40
20
0

1 00
C
•
E
•
II
•

Ii.
·
Ci
'#

80

Ventro-dorsal nucleus thalami

1 00

�

�

80
80
40

t

20

-

,

0

Ventral nucleus thalami

�

0

3

2

0

1 00

� -4

60

40

40

20

20

0

0

1
2
Log Cone (jiM)

100
C

•
E
•
II
•

Ii.
•
Ci
'#

80
60

3

3

Lateral nucleus thalami

�

80

60

2

0

0

1
2
Loa Cone CuM)

3

Medial habenula

�

40
20
0

0

2
1
Log Cone (jiM)

3

Figure 1 3 . Displacement of 3H-L-nicotine binding to regions in section A4400 by nicotine
and pempidine
).

(.

( D)

66

Cortex

1 00
C

80

..

80

•
E
•
•

"ii.
·
Q
�

40

100
C

�•
..

80

40
20

0

2

3

80

40
20
0

0

Reticular formation

1 00

80

•

"ii.
·
is
�

80

�

20
0

80

r-+--Y

80

r+-

20

0

2

0

2

3

Medial geniculate nucleus

�

40

3

Stratum griseum-superior coIIiculus

1 00

0

1 00

C

80

..

80

80

40

40

20

20

•
E
•

Hippocampus

1 00

�

80

0

2

3

Interpeduncular nucleus

�

·

"ii.
•
is
�

0

0

1
2
Log Cone 111M)

3

0

0

1
2
Log Cone 111M)

3

Figure 14. Displacement of 3H-L-nicotine binding to regions in section A 1 800 by nicotine
and pempidine ( . ).

( D)

67

PHJ-Pempidine bindin� to rat brain in vitro and in situ
The binding of 3H-pempidine to mouse brain homogenate was studied under a number
of conditions

in vitro.

Under the same conditions used for 3H-L-nicotine binding,

3H-pempidine was not found to bind in a manner consistent with receptor binding, as can
be seen in figure 15. Pempidine did not displace 1 nM of 3H-pempidine from brain
homogenate in a saturable manner as the greatest amount of displaceable binding was only
5% of the total binding at 1O �. The time course of 3H-pempidine binding was assessed
at 37 °C. The greatest amount of displaceable 3H-pempidine binding in the presence of 10
11M pempidine was found at 90 min and represented only 30 ± 3 % of the total binding.
Increasing the number of washes of the filters with ice-cold buffer did not significantly
increase the % specific binding.
Investigation of 3H-pempidine binding
conditions led to similar results as

in situ

in vitro.

to rat brain slices under a number of

3H-Pempidine binding under the same

conditions as 3H-nicotine produced an isotherm and Scatchard plot inconsistent with
receptor binding, as can be seen in figure 1 6. The time course of 3H-pempidine binding
was also assessed at 4, 25 and 37 °C. At no time or temperature was the displaceable
binding found to be greater than 40 % of the total binding. No significant difference was
found in the ability of 3H-pempidine to bind to various brain sections from A l O,OOO to
A 1 200 as well. Athough the greatest amount of specific binding was found in sections rich
in thalamic nuclei, it represented less than 35 % of the total binding. Varying the time of
wash from 2 sec to 2 min did not significantly increase the percentage of specific binding.
Nicotine was found to increase the amount of displaceable 3H-pempidine binding, which
was neither concentration nor temperature dependent The greatest amount of displaceable
3H-pempidine binding was found with 50 nM nicotine at 4 °C and represented only 25 %
of the total binding. Utilizing a 10 mM HEPES buffer or a 50 mM Tris buffer, both at
pH=7.4, did not result in an increase in the amount of 3H-pempidine binding.
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Figure

15.

3H-Pempidine binding to mouse brain

in vitro
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Discussjon
The characterization of central 3H-L-nicotine binding sites

in vitro

and in situ revealed

similar findings. The K.! and Bmax values for the two 3H-L-nicotioe binding sites in vitro
and in situ were found to be similar. Also, the displacement of 3H-L-nicotine binding to
the high-affinity binding site by various cholinergic compounds was similar to what has
been found

in vitro

(Marks and Collins, 1982; Scimeca and Martin, 1988). Neither

cholinergic agonists nor antagonists have been found to displace 3H-L-nicotioe binding to a
low-affinity binding site (Scimeca and Martin, 1988).

The nicotinic antagonists

hexamethonium, mecamylamine, and pempidine were not found to compete for this
binding in situ with high affmity. Similar findings in vitro have led some investigators to
conclude that these compounds act as noncompetitive antagonists in the CNS (Marks and
Collins, 1982), although pharmacological evidence is lacking. Romano and Goldstein
( 1980) have suggested that the long incubation times used for agonist binding may shift the
receptor into an agonist-selective state, and that binding studies may be a poor indicator of
mechanism of action. Another possibility is that the homogenization of the brain tissue
alters the 3H-L-nicotine high-affinity binding site in a manner that renders it
antagonist-insensitive. The inability of the antagonists to displace 3H-L-nicotine binding to
brain slices suggests that homogenization alone does not render the high-affmity binding
site antagonist-insensitive.
Autoradiographic localization of 3H-L-nicotine binding to brain slices revealed a pattern
consistent with that reported previously (Clarke et al., 1 984; Marks et al. , 1 9 86a).
3H-L-Nicotine binding sites were found to be most plentiful in regions containing
cholinergic innervation (Hoover et al., 1978; Armstrong et al., 1983; Mesulam et al.,
1983). The most dense labelling was found in the interpenduc1ar nucleus, and several
investigators have found evidence for cholinergic innervation of this area (Lake, 1973;
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Cuello e t al., 1978; Sastry,1978; Ogata, 1979; Sastry et al., 1 979; Vincent e t aI., 1 980).
An increase in fIring rate of neurons has been found following ionophoretic application of
acetycholine and carbachol into the interpeduncular nucleus of rats (Brown et aI. , 1 983).
The action of both of these compounds was antagonized by hexamethonium,
d-tubocurarine, and mecamylamine. Similar results were found in rat brain slices with
carbachol. This study suggests that functional nicotinic receptors are contained in the
interpeduncular nucleus and that mecamylamine acts to antagonize the effects of agonists on
neurons in this area.

Pempidine, however, was not found to compete

in situ

for

3H-L-nicotine binding in this region with relatively high affinity, as can be seen in fIgure
14.
Dense labelling o f the medial habenula and striatum was also found with 3H-L-nicotine.
The medial habenula has been shown to project cholinergic efferents to the interpeduncular
nucleus and receive afferent innervation from the nucleus triangularis septi as well as other
nuclei from the postcommissural septum (Herkenham and Nauta, 1977).

SpecifIc

interactions between nicotine and nicotinic antagonists have not been documented in this
region. The effects of nicotine on neurons in the striatum have been documented by a
number of investigators. Giorguieff et al. ( 1 975) found that acetylcholine and carbachol
increased the release of newly synthesized dopamine in vitro from rat striatal slices and in
vivo from cat

caudate nucleus and that both agonists were antagonized by mecamylamine.

Giorguieff et al. ( 1 976) likewise demonstrated that pempidine would antagonize
acetylcholine's stimulation of dopamine release from rat striatal slices. As can be seen in
fIgures 12 and 1 3, pempidine did not compete effectively for 3H-L-nicotine binding to
either of these sites.
Collinridge and Davies ( 1980) have demonstrated that acetylcholine increases the fIring
rate of neurons in the substantia nigra pars reticulata. Nicotine has also been shown to
increase

the fIring rate of neurons in the substantia nigra pars reticulata in rats when

administered by either iontophoresis or subcutaneous injection (Lichtensteiger et al., 1 982).
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Iontophoresis of dihydro-Il-erythroidine into this region antagonized nicotine's effect.
Clarke et al. (1 985) have likewise shown that nicotine given intravenously stimulates the
firing rate of single units in the substantia nigra pars reticulata and that this effect is
completely antagonized by mecamylamine. These investigators suggested that peripheral
mechanisms

are

also involved in this action of nicotine in that the bisquaternary ganglionic

blocker chlorisondarnine antagonized most of nicotine's effects when given intravenously.
The effects of nicotine and nicotinic antagonists on the other areas found to contain large
numbers of 3H-L-nicotine binding sites has not been documented.
3H-L-Nicotine binding was found to be dense in those areas in which nicotine has been
shown to possess effects on neurotransmitter release and neuronal firing rate which are
antagonized by mecamylamine and pempidine. The experiments cited above unfortunately
do not address the issue of competitive or noncompetitive antagonism of nicotine by these
compounds. The inability of pempidine to effectively displace 3H-L-nicotine binding to all
of these areas clearly demonstrates that these compounds do not compete for the agonist
binding sites that have been elucidated to date. These findings show that the inability to
detect displacement of agonist binding by the antagonists is not due to the inability to
measure the binding in areas that are specifically rich in nicotine binding sites by in

vitro

techniques. Therefore, nicotinic antagonists do not compete effectively for 3H-L-nicotine
in situ

binding even in specific brain regions containing a large density of nicotine binding

sites, suggesting that pempidine is a noncompetitive antagonist of nicotine.
Evidence for the noncompetitive nature of pempidine's antagonism of nicotine is further
strengthened by the lack of 3H-pempidine binding under conditions that result in
high-affinity agonist binding. Since nicotine did not affect the binding of 3H-pempidine to
brain

tissue, it is unlikely that the inability of these compounds to displace agonist binding

can be explained by an agonist-induced shift of the receptor to an antagonist-insensitive
state, as suggested by Romano and Goldstein ( 1 9 80). The inability of 3H-pempidine to
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bind to brain tissue is surprising due to its relatively potent antagonistic properties.
However, it is clear that if a binding site exists for the antagonists, its characteristics are
distinct from those of the agonist binding sites that have been elucidated to date. The
results of these binding studies with both nicotine and pempidine suggest that these
compounds act at mutually exclusive sites.
The elusive issue that these studies do not addres s is the functional significance of these
3H-L-nicotine binding sites and their relevance to nicotine's phannacology. Although it is
clear that pempidine neither competes for 3H-L-nicotine binding to specific nuclei rich in
agonist binding sites nor binds to brain tissue itself under conditions maximized for agonist
binding, one cannot conclude that pempidine is a noncompetitive antagonist of all of
nicotine's effects based on binding studies alone. Several investigators have argued that
these high-affinity binding sites have functional significance based on the fact that
upregulation occurs following chronic treatment (Marks et al., 1983; Schwartz and Kellar,
1 983).

This may suggest however, that the high-affinity states are associated with

tolerance and receptor desensitization as opposed to behavioral effects and receptor
activation.

Such a model has been proposed for nicotinic receptors in electric eel

(Conti-Tranconi et al., 1982).
Other strong evidence in favor of the functional significance of these high-affinity
binding sites is that the localization patterns for nicotine's metabolic effects and
high-affinity binding sites are well correlated (London, 1985). However, if the sites that
lead to receptor desensitization and activation are present on the same macrocolecule, such a
f"mding would not be unexpected. Nicotine has been shown to cause both activation and
desensitization of

purified, reconstituted nicotinic receptors from electroplaque

(Conti-Tranconi et aI., 1982). These investigators suggest that distinct agonist binding
sites modulate these effects that are present on the same macromolecule. The fact that
mecamylamine completely antgonizes nicotine's metabolic effects and yet does not displace
agonist binding even at micromolar concentrations suggests that these binding sites may not
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mediate the behavioral and metabolic effects of nicotine. It is interesting that nicotine's
effects on neurotransmitter release and neuronal excitation cited above occur only at
micromolar concentrations.

This brings the relevance of agonist binding sites of

nanomolar affinity into question. Of course, it is possible that the preparations used can
only detect effects that are reasonably large compared to those necessary for nicotine to
exert behavioral effects in the whole animal. However, nicotine has been shown to
produce antinociception only at doses that result in micromolar concentrations in plasma
(Tripathi et al. , 1982). Therefore, central nicotinic antagonists do not compete for
high-affinity 3H-L-nicotine binding to relevant brain areas, suggesting that either these
compounds are noncompetitive antagonists, or that these high-affmity agonist binding sites
do not mediate nicotine's behavioral, biochemical, or electrophysiological effects in brain.

IV. General Discussion

The research presented in this thesis was undertaken to address the ambiguity of the
mechanism of action of nicotinic antagonists in the brain.

The assumption of

noncompetitive antagonism of nicotine by these compounds has been based largely upon
the fact that they do not displace 3H-nicotine or 3H-acetylcholine binding to brain tissue
vitro.

Pharmacological studies to corroborate this assumption

are

in

lacking, however. The

study by Stolerrnan et al. ( 1 987) using drug discrimination was difficult to interpret due to
confounding behavioral effects of nicotine. Although the mechanims of action of these
compounds has been studied extensively in the periphery, there is some discrepancies
regarding their competitive or noncompetitive nature at the ganglion as well (van Rossum et
al., 1 962). The recent findings that peripheral and central nicotinic cholinergic receptors
display distinct biochemical characteristics makes extrapolation of these findings to the
brain even more difficult (Whiting and Lindstrom, 1988).
Two assays for nicotine's central effects, namely depression of spontaneous activity
and antinociception, were chosen for the evaluation of pempidine's antagonism of nicotine.
The range of doses of nicotine that could be studied was greater than for drug
discrimination due to fewer confounding behavioral effects. Pempidine displayed different
characteristics with regard to antagonism of these effects of nicotine. The antagonism of
nicotine-induced hypoactivity displayed the characteristics of competitive antagonism,
wheras antinociception produced by nicotine was antagonized by pempidine in a
noncompetitive manner. It is possible that two mechanisms for the antagonists exist, one
75
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that is competitive and another being noncompetitive. However, the structure-activity
relationship of analogs of mecamylamine's antagonism of these effects of nicotine does not
suggest two distinct mechanisms. The structural requirements for antagonism of nicotine's
depression of spontaneous activity and production of antinociception were found to be
identical.

If the

agonists and antagonists shared common binding sites for modulation of

motor activity, but not for pain modulation, then the structural requirements for antagonism
of these effects should be different. The structure-activity relationship that was found for
the antagonists was different than what has been previously reported for nicotinic agonists
in the brain (Martin, 1986).
There are other possible explanations for this discrepancy. Stolennan ( 1 987) has
postulated that central depression is a nonspecific effect of nicotine, although antagonism of
this effect by pempidine and mecamylamine suggests that this is a receptor-mediated effect
of nicotine. Higher doses of niCotine may cause central depression through non-receptor
mediated mechanisms that are not antagonized by pempidine. Noncompetitive antagonism
of spare nicotine receptors for depression of spontaneous activity by pempidine is another
possible explanation for the inability of pempidine to decrease the maximum effect of
nicotine in this assay. The pattern of shift of nicotine's dose-response curves for these
central effects, coupled with the structure-activity studies, do not support a competitive
action of these antagonists.
These data therefore suggest that mecamylamine and pempidine act noncompetitively in
the brain.

However, the structural requirements for antagonism of these effects were found

to be quite minimal. It is possible that the structural changes made in the molecule are not
sufficient to delineate between multiple mechanisms for these compounds. Arguments
against a competitive mechanism of action for these compounds have bee n based largely on
in vitro

binding assays in which the antagonists have not been shown to compete

effectively for agonist binding (Marks et al., 1986). However, such assays have limited
sensitivity for discrete brain regions and destroy the integrity of the tissue by
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homogenization. Therefore, in situ studies were perfonned to detennine if the lack of
sensitivity of the agonist binding sites to displacement by the antagonists is due to
homogenization of the tissue. Autoradiographic localization of 3H-L-nicotine binding and
its displacement by pempidine was perfonned to test the hypothesis that the antagonists
may compete for a subset of agonist binding sites that cannot be chartacterized due to the
lack of sensitivity of in vitro assays.
The in situ binding and autoradiography studies strongly suggest that neither of these
issues are responsible for the lack of ability to find displacement of 3H-L-nicotine binding
to

brain tissue by the antagonists. Pempidine did not effectively displace agonist binding to

any of the areas studied. However, these studies did not address the other explanations
that have been offered with regard to the antagonist's lack of ability to displace agonist
binding, namely that the agonists are capable of inducing an agonist-selective state of the
receptor and thereby preventing antagonist binding (Romano and Goldstein, 1 980).
Therefore, binding studies with 3H-pempidine were conducted to address these issues and
to determine if the chartacteristics of agonist and antagonist binding to brain are similar.
The binding studies with 3H-pempidine in vitro and in situ clearly demonstrate that, if an
antagonist binding site exists, its characteristics are undoubtedly different from the agonist
binding sites that have been elucidated to date. The inability of 3H-pempidine to bind to
brain tissue in a saturable manner under the myriad of conditions studied suggest quite
strongly that the antagonists do not interact with the agonist binding sites that are labelled
by these methods. These studies, taken together with the behavioral studies, demonstrate
that pempidine and mecamylamine are noncompetitve antagonists of nicotine in the brain

.

The noncompetitive nature of these compounds introduces several important questions
pertaining

to

nicotine's pharmacology. Since these compounds do not appear to share a

binding site with acetylcholine, then there may be some other endogenous compound that
serves as a nicotinic agonist or antagonist centrally. The identification of such a compound
would greatly enhance the knowledge of nicotine's pharmacology and of the nicotinic
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cholinergic system. This compound may serve t o modulate cholinergic function i n the
CNS and therefore have a role in nicotine dependence as well as pathological states
associated with cholinergic disfunction. Mecamylamine has been shown to increase
smoking in humans (Stolerman et ai., 1973). Comparisons of the levels of a putative
endogenous nicotinic antagonist in smokers and nonsmokers may yield insights into the
mechanism by which nicotine reinforces the use of tobacco. Similar studies in animals
might yield insights into the fundamental reinforcing properties of the nicotinic cholinergic
system. Loss of cortical nicotinic receptors and basal forebrain cholinergic function has
been shown to be the most consistent findings associated with Alzheimer's disease
(Whitehouse and Kellar, 1987). Furthermore, the degree of senile dementia and other
symptoms of this disorder have been shown to be correlated with the degree of neuronal
loss (Whitehouse and Kellar, 1987). Similar fmdings have also been reported for dementia
associated with Parkinson's disease (Whitehouse et al., 1986). It is therefore feasible that
an endogenous antagonist of the nicotinic cholinergic system may have a role in this
disorder, as well as senile dementia that is not due to Alzheimer's disease. Nicotine has
been shown to increase learning and memory in humans and animals (Wesnes and
Warburton, 1984; Iwamoto et al., 1987). Therefore, the noncompetitive nature of nicotinic
antagonists in the CNS poses interesting questions pertaining to nicotine's pharmacology.
The inability of these antagonists to bind to brain tissue is puzzling due to the potency
and specificity

of

their action.

It is possible that these compounds interact with

conformation of the nicotinic receptor that exists only

in vivo.

a

These compounds

antagonize practically all of nicotine's elecrrophysioiogical, biochemical, and behavioral
effects regardless of the type of tissue and species studied, suggesting that the aspects of
the nicotinic cholinergic receptor involving the antagonists have been preserved

throughout

the evolution of this system. The study of the relationship between the agonists and
antagonists would be greatly enhanced if radioligand binding could be studied with
functional nicotinic receptors. Correlations of the affinity of the receptor for the agonist
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with receptor desensitization may provide insights into the issue of the functional
significance of the high-affinity binding sites. Such a preparation may also be necessary
for the antagonists to bind to their receptor, if such a receptor exists. These studies could
be performed

in vivo

in awake animals or possibly

ex

vivo

to superfused brain slices.

Nicotine has been shown to release dopamine from striatal slices in such a preparation
(Giorguieff et al., 1975). This effect is antagonized by mecamylamine (Giorguieff et al.,
1 975) and pempidine (Giorguieff et al. , 1 976).

Although this research clearly

demonstrates that mecamylamine and pempidine do not act at the same binding site as
nicotinic agonists, the mechanism by which this antagonism occurs is unknown.
Noncompetitve antagonism could occur if the antagonists bind to an allosteric site on the
nicotinic receptor-ionophore complex that results in channel blockade or inactivation.
Alternatively, this binding could result in accelerated dissociation of the agonists from their
binding site.

The most appropriate way to address these issues is by correlating

electrophysiological, biochemical, or behavioral effects of the agonists and antagonists with
receptor binding in the same preparation.
The research presented in this thesis demonstrates that mecamylamine and pempidine
do not display the characteristics of competitive antagonism of nicotine in the brain. The
differences in the structural requirements for agonistic and antagonistic potency suggest that
nicotine and mecamylamine act at different sites in the brain. The binding studies with
PH]-nicotine and [3H]-pempidine support this conclusion. Therefore, mecamylamine and
pempidine antagonize nicotine in the brain through a noncompetitive mechanism of action.
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